[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1435
1. Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ: Chemoprevention for colon cancer: new opportunities, fact or fiction? Scand J Gastroenterol Suppl; 2006;(243):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention for colon cancer: new opportunities, fact or fiction?
  • Substantial evidence has shown that non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors can reduce the incidence and mortality of CRC.
  • Ursodeoxycholic acid has been shown to decrease the incidence of colonic dysplasia in patients with ulcerative colitis and PSC and possibly reduces recurrence rates of polyps in general.
  • In parallel with primary prevention strategies in vascular medicine, the aim might be to postpone adenoma formation, for instance for 10 years, thereby achieving a significant risk reduction for CRC.
  • [MeSH-minor] Age Factors. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Aspirin / administration & dosage. Colonic Neoplasms / etiology. Colonic Neoplasms / prevention & control. Europe / epidemiology. Folic Acid / administration & dosage. Humans. Inflammatory Bowel Diseases / complications. Inflammatory Bowel Diseases / epidemiology. Inflammatory Bowel Diseases / pathology. Population Surveillance. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782636.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 935E97BOY8 / Folic Acid; R16CO5Y76E / Aspirin
  • [Number-of-references] 69
  •  go-up   go-down


2. Mecklin JP, Järvinen HJ: Surveillance in Lynch syndrome. Fam Cancer; 2005;4(3):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, screening for colorectal adenomas and carcinomas by regular colonoscopies is the main topic of the present review.
  • Observational studies indicate that the adenoma carcinoma sequence is the main pathway in the development of colorectal cancer in Lynch syndrome.
  • A colonoscopy every 1-3 years starting at age 20 to 25 years and the removal of observed adenomas is recommended for individuals known to have Lynch syndrome associated mutations.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3629-37 [14512394.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1675-8 [7979205.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Med Genet A. 2003 Aug 30;121A(2):159-62 [12910497.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):44-50 [10719730.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] JAMA. 1997 Mar 19;277(11):915-9 [9062331.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):67-71 [9841970.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):17-25 [15236168.001]
  • [Cites] Ann Intern Med. 1998 Nov 15;129(10):787-96 [9841584.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1708-12 [11920532.001]
  • [Cites] Cancer Detect Prev. 2001;25(6):503-10 [12132870.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):273-9 [11852345.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):422-5 [8621220.001]
  • [Cites] Langenbecks Arch Surg. 2003 Mar;388(1):9-16 [12690475.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1001-12 [12907889.001]
  • [Cites] Lancet. 1995 May 6;345(8958):1183-4 [7723574.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1014-9 [11861375.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Am J Med Genet A. 2004 Mar 15;125A(3):318-9 [14994245.001]
  • [Cites] J Med Genet. 2001 May;38(5):318-22 [11333868.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1250-3; discussion 1253-5 [9788388.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):328-36 [12891533.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] Int J Cancer. 1995 Dec 20;64(6):430-3 [8550246.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):142-4 [10508506.001]
  • [Cites] Ann Intern Med. 2001 Oct 16;135(8 Pt 1):577-88 [11601929.001]
  • [Cites] JAMA. 1999 May 5;281(17):1618-22 [10235155.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):882-7 [14970868.001]
  • [Cites] Cancer. 1998 May 1;82(9):1632-7 [9576281.001]
  • [Cites] Gut. 2003 Dec;52(12):1752-5 [14633956.001]
  • [Cites] Am J Hum Genet. 1997 Aug;61(2):329-35 [9311737.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Int J Cancer. 2002 Nov 10;102(2):198-200 [12385019.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21 Suppl):81S-92S [11060333.001]
  • (PMID = 16136388.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 40
  •  go-up   go-down


3. Meza R, Jeon J, Renehan AG, Luebeck EG: Colorectal cancer incidence trends in the United States and United kingdom: evidence of right- to left-sided biological gradients with implications for screening. Cancer Res; 2010 Jul 1;70(13):5419-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the Surveillance Epidemiology and End Results (SEER) and the Office for National Statistics (ONS) registries (both 1973-2006), we derived stochastic multistage clonal expansion (MSCE) models for right-sided (proximal colon) and left-sided (distal colon and rectal) tumors.
  • The MSCE concept is based on the initiation-promotion-progression paradigm of carcinogenesis and provides a quantitative description of natural tumor development from the initiation of an adenoma (via biallelic tumor suppressor gene inactivation) to the clinical detection of CRC.
  • From 1,228,036 (SEER: 340,582; ONS: 887,454) cases, parameter estimates for models adjusted for calendar-year and birth-cohort effects showed that adenoma initiation rates were higher for right-sided tumors, whereas, paradoxically, adenoma growth rates were higher for left-sided tumors.
  • The net effect was a higher cancer risk in the right colon only after age 70 years.
  • Consistent with this finding, simulations of adenoma development predicted that the relative prevalence for right- versus left-sided tumors increases with increasing age, a differential effect most striking in women.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1863-72 [17079760.001]
  • [Cites] J Theor Biol. 2000 Nov 21;207(2):129-43 [11034825.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):847-52 [12378628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15095-100 [12415112.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1400-9 [12818288.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):72-7 [15017635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1215-22 [15247133.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):969-74 [2375325.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):84-7 [2049758.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):941-5 [1858757.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):946-51 [1858758.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):664-71 [17096321.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2815-22 [17179458.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):96-102 [17241863.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Math Biosci. 2008 May;213(1):56-70 [18374369.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2828-38 [18539961.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1360-7 [18539928.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):532-5 [18628760.001]
  • [Cites] JAMA. 2008 Sep 24;300(12):1417-22 [18812532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16284-9 [18936480.001]
  • [Cites] JAMA. 2008 Dec 17;300(23):2765-78 [19088354.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):50-2 [19075200.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33 [19261858.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2410-9 [19288570.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):547-63 [19207714.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2027-33 [19289271.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jul;7(7):770-5; quiz 711 [19268269.001]
  • [Cites] Colorectal Dis. 2009 Sep;11(7):689-701 [19207713.001]
  • [Cites] Gut. 1992 Jan;33(1):71-8 [1740282.001]
  • [Cites] Surg Radiol Anat. 1992;14(3):251-7 [1440190.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Am J Gastroenterol. 1993 Jun;88(6):825-31 [8503374.001]
  • [Cites] Arch Intern Med. 1995 Sep 11;155(16):1741-8 [7654107.001]
  • [Cites] Math Biosci. 2005 Oct;197(2):188-210 [16087198.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1142-52 [16835912.001]
  • [Cites] Gastrointest Endosc. 2000 Jul;52(1):1-8 [10882954.001]
  • (PMID = 20530677.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107028-04; United States / NCI NIH HHS / CA / R01 CA107028; United States / NCI NIH HHS / CA / R01 CA107028-04; United States / NCI NIH HHS / CA / R01 CA107028-05A1; United States / NCI NIH HHS / CA / CA107028-05A1; United States / NCI NIH HHS / CA / R01 CA119224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS205243; NLM/ PMC2914859
  •  go-up   go-down


Advertisement
4. Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, Sieber O, Santander S, Pringle JH, Mandir N, East P, Obszynska J, Sanders S, Piazuelo E, Shaw J, Harrison R, Tomlinson IP, McDonald SA, Wright NA, Jankowski JA: Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res; 2008 Oct 01;68(19):7760-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo.
  • P-cadherin is normally expressed in the basal layer of squamous epithelia and absent from the healthy intestine and colon.
  • We have previously shown it to be expressed in all inflamed, hyperplastic, and dysplastic intestinal and colonic mucosa.
  • This study aimed to better understand the mechanisms controlling the expression of P-cadherin and the biological effects of its ectopic presence in the intestine and colon.
  • The CDH3 promoter was hypomethylated in colonic aberrant crypt foci, in CRC, and, occasionally, in the normal epithelium adjacent to cancer, demonstrating a potential "field effect" of cancerization.
  • The hypomethylation was also associated with induction of P-cadherin expression in the neoplastic colon (P < 0.0001).
  • We then created transgenic mice that overexpressed P-cadherin specifically in the intestinal and colonic epithelium under the liver fatty acid binding protein promoter.
  • Forced ectopic expression of P-cadherin accompanied by indomethacin-induced inflammation resulted in a 3-fold higher crypt fission rate within the small and large intestines in the homozygous mice compared with the wild-type animals (P < 0.02).
  • We conclude that epigenetic demethylation of the P-cadherin promoter in the human intestine permits its ectopic expression very early in the colorectal adenoma-carcinoma sequence and persists during invasive cancer.
  • [MeSH-major] Adenoma / genetics. Cadherins / genetics. Cell Proliferation. Colorectal Neoplasms / genetics. DNA Methylation. Intestinal Mucosa / pathology. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2001 Mar;48(3):367-71 [11171827.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):573-9 [9842964.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4632-42 [15542813.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):24088-96 [11301329.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):599-611 [11522744.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Breast Cancer Res. 2001;3(5):289-93 [11597316.001]
  • [Cites] Gut. 2002 Apr;50(4):513-9 [11889072.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E101-8 [11944044.001]
  • [Cites] J Pathol. 2002 Jun;197(2):194-200 [12015743.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2055-61 [12057910.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12495-506 [12551911.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3819-25 [12839979.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29954-62 [12771132.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:207-35 [14570569.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2385-400 [14767473.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3272-83 [15077190.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1507-15 [15016659.001]
  • [Cites] Am J Pathol. 1986 Jul;124(1):34-8 [3728646.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):2128-33 [2702654.001]
  • [Cites] J Cell Biol. 1989 Oct;109(4 Pt 1):1787-94 [2793940.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2185-92 [2009537.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Inflammation. 1993 Dec;17(6):641-62 [7906675.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):605-12 [7534041.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Am J Pathol. 1995 Nov;147(5):1416-27 [7485404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9588-93 [8790374.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3092-9 [15833838.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34 [16025097.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Gut. 2007 Jan;56(1):140-8 [16840508.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):289-96 [17008425.001]
  • [Cites] Science. 2007 Feb 16;315(5814):1006-10 [17255475.001]
  • [Cites] FEBS Lett. 2007 Mar 6;581(5):831-6 [17292359.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] Cell Prolif. 2007 Apr;40(2):231-40 [17472729.001]
  • [Cites] J Pathol. 2008 Jun;215(2):184-94 [18393367.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] J Pathol. 1998 Jul;185(3):246-55 [9771477.001]
  • (PMID = 18829530.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A4584; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  • [Other-IDs] NLM/ PMC2561210; NLM/ UKMS2285
  •  go-up   go-down


5. Ahmed FE, Vos P, iJames S, Lysle DT, Allison RR, Flake G, Sinar DR, Naziri W, Marcuard SP, Pennington R: Transcriptomic molecular markers for screening human colon cancer in stool and tissue. Cancer Genomics Proteomics; 2007 Jan-Feb;4(1):1-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptomic molecular markers for screening human colon cancer in stool and tissue.
  • There is a need for sensitive and specific diagnostic molecular markers that can be used to monitor early patterns of gene expression in non-invasive exfoliated colonocytes shed in the stool, and in situ in adenoma-carcinoma epithelium of the colon.
  • By routinely and systematically being able to perform quantitative gene expression studies on these samples using less than ten colon cancer genes selected by the enormous resources of the National Cancer Institute's Cancer Genome Anatomy Project, we were able to monitor changes at various stages in the neoplastic process, allowing for reliable diagnostic screening of colon cancer particularly at the early, pre-malignant stages.
  • Thus, a transcriptomic approach using stool or tissue samples promises to offer more sensitivity and specificity than currently used molecular screening methods for colon cancer.
  • A larger prospective clinical study utilizing stool and tissue samples derived from many control and colon cancer patients, to allow for a statistically valid analysis, is now urgently required to determine the true sensitivity and specificity of the transcriptomic screening approach for this preventable cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colon / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / genetics. Feces / chemistry. Gene Expression Regulation, Neoplastic. Mass Screening. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726236.001).
  • [ISSN] 1109-6535
  • [Journal-full-title] Cancer genomics & proteomics
  • [ISO-abbreviation] Cancer Genomics Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


6. Singh M, Dhindsa G, Friedland S, Triadafilopoulos G: Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther; 2007 Oct 1;26(7):1051-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas.
  • BACKGROUND: The clinical significance of the trophic effects of long-term proton pump inhibitors (PPI)-related hypergastrinemia on colon polyps remains unknown.
  • AIM: To study the frequency, growth, and histology of colon polyps in patients on chronic PPI therapy (cases), compared to those not receiving acid suppression (controls).
  • RESULTS: Demographics and risk factors for colon cancer were comparable between the two groups.
  • At baseline the mean frequency and size of adenomatous polyps were similar in cases and controls (P > 0.05) and at follow-up, these were 0.89 and 1.18 (P > 0.05; 95% CI of -0.08 to 0.66) and 4.09 mm and 4.00 mm (P > 0.05; 95% CI -2.29 to 2.11), respectively with no significant change.
  • However, control group had a higher mean frequency and size of hyperplastic polyps at baseline as well as at follow-up colonoscopy (P < 0.05).
  • CONCLUSIONS: The long-term use of PPI does not influence the frequency, growth, or histology of adenomatous polyps, but is associated with a reduction in both baseline and interval development of hyperplastic polyps.
  • [MeSH-major] Adenomatous Polyps / drug therapy. Colonic Polyps / drug therapy. Proton Pump Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877512.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK063624
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


7. Oikarinen SI, Pajari AM, Salminen I, Heinonen SM, Adlercreutz H, Mutanen M: Effects of a flaxseed mixture and plant oils rich in alpha-linolenic acid on the adenoma formation in multiple intestinal neoplasia (Min) mice. Br J Nutr; 2005 Oct;94(4):510-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a flaxseed mixture and plant oils rich in alpha-linolenic acid on the adenoma formation in multiple intestinal neoplasia (Min) mice.
  • To study the effects of a flaxseed mixture on adenoma formation in multiple intestinal neoplasia mice, the mice were fed a diet containing 2.7 % flaxseed, 4.5 % fibre and 3.7 % ALA.
  • The median number of adenomas in the small intestine was fifty-four for the control group, and thirty-seven (P=0.023) and forty-two (P=0.095) for flaxseed and oil groups, respectively.
  • Compared with controls (1.2 mm), the adenoma size was smaller in the flaxseed (0.9 mm; P=0.002) and oil (1.0 mm; P=0.012) groups.
  • Both diets changed the proportions of n-3 and n-6 fatty acids in the colonic mucosa.
  • Membrane beta-catenin and protein kinase C (PKC)-zeta levels were reduced in the adenoma v. mucosa (P<0.05), and an inverse association was found between the membrane PKC-zeta in the mucosa and the adenoma number (r -0.460, P=0.008, n 32).
  • The results suggest that the preventive effect of flaxseed on colon carcinogenesis may be due to the oil part of flaxseed, and the loss of beta-catenin and PKC-zeta from the membranes of the mucosal tissue may play a permissive role in intestinal tumour development.
  • [MeSH-major] Adenoma / prevention & control. Flax. Intestinal Neoplasms / prevention & control. Neoplasms, Multiple Primary / prevention & control. Plant Oils / administration & dosage. alpha-Linolenic Acid / administration & dosage
  • [MeSH-minor] Actins / analysis. Animals. Blotting, Western / methods. Colon / chemistry. Cyclooxygenase 2 / analysis. Fatty Acids / analysis. Intestinal Mucosa / chemistry. Lignans / metabolism. Linseed Oil / metabolism. Mice. Mice, Mutant Strains. Models, Animal. Protein Kinase C / analysis. Weight Gain. beta Catenin / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LINSEED OIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197574.001).
  • [ISSN] 0007-1145
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Fatty Acids; 0 / Lignans; 0 / Plant Oils; 0 / beta Catenin; 0RBV727H71 / alpha-Linolenic Acid; 8001-26-1 / Linseed Oil; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


8. Jung B, Påhlman L, Nyström PO, Nilsson E, Mechanical Bowel Preparation Study Group: Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. Br J Surg; 2007 Jun;94(6):689-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection.
  • This randomized clinical trial assessed whether preoperative MBP is beneficial in elective colonic surgery.
  • METHODS: A total of 1505 patients, aged 18-85 years with American Society of Anesthesiologists grades I-III, were randomized to MBP or no MBP before open elective surgery for cancer, adenoma or diverticular disease of the colon.
  • CONCLUSION: MBP does not lower the complication rate and can be omitted before elective colonic resection.
  • [MeSH-major] Cathartics / therapeutic use. Colonic Diseases / surgery. Enema / utilization. Postoperative Complications / prevention & control. Sepsis / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 British Journal of Surgery Society Ltd.
  • [CommentIn] Br J Surg. 2007 Oct;94(10):1306; author reply 1306 [17874443.001]
  • (PMID = 17514668.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN28535118
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cathartics
  •  go-up   go-down


9. M Bustamante-Balén, Bernet L, Cano R, Morell L, López A: Assessing the reproducibility of the microscopic diagnosis of sessile serrated adenoma of the colon. Rev Esp Enferm Dig; 2009 Apr;101(4):258-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the reproducibility of the microscopic diagnosis of sessile serrated adenoma of the colon.
  • INTRODUCTION: sessile serrated adenoma (SSA) is a recently described lesion that may be related to the development of up to 15% of colorectal cancers (CRCs).
  • MATERIAL AND METHODS: concordance between two pathologists in the diagnosis of serrated lesions of the colon was studied for 195 lesions (187 hyperplastic polyps and 7 serrated adenomas).
  • Possible diagnoses were: SSA, traditional serrated adenoma (TSA), hyperplastic polyp (HP), serrated polyp, tubular adenoma, or mixed lesions.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology


10. Hu Y, Lu X, Luo G: Effect of Recql5 deficiency on the intestinal tumor susceptibility of Apc(min) mice. World J Gastroenterol; 2010 Mar 28;16(12):1482-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Recql5 deficiency in Apc(min/+) mice resulted in a significant increase in the tumor incidence in both the colon (P = 0.0162) and the small intestine (P < 0.01).
  • Importantly, since mouse Recql5 and human RECQL5 are highly conserved, these findings also suggest that RECQL5 may be a tumor suppressor for human colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Genet. 2001 Mar;2(3):196-206 [11256071.001]
  • [Cites] J Biol Chem. 2009 Aug 28;284(35):23197-203 [19570979.001]
  • [Cites] Semin Cancer Biol. 2002 Aug;12(4):261-6 [12147207.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:337-66 [15473844.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29;353(1370):915-23 [9684289.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Hum Mol Genet. 2005 Mar 15;14(6):813-25 [15703196.001]
  • [Cites] Mol Cell Biol. 2005 May;25(9):3431-42 [15831450.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Genes Dev. 2007 Dec 1;21(23):3073-84 [18003859.001]
  • [Cites] Biochem J. 2008 Aug 1;413(3):505-16 [18419580.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Mol Biol Cell. 2009 Jan;20(1):114-23 [18987339.001]
  • [Cites] Trends Mol Med. 2002 Apr;8(4):179-86 [11927276.001]
  • (PMID = 20333788.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA103736; United States / NCI NIH HHS / CA / R01 CA88939
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 3.6.4.12 / RecQ Helicases; EC 5.99.- / Recql5 protein, mouse
  • [Other-IDs] NLM/ PMC2846253
  •  go-up   go-down


11. Smith FB, Aksenov S: Potential role of nuclear appearance in pathologic recognition and delimitation of sessile serrated polyps of the colon: a karyometric study. Anal Quant Cytol Histol; 2007 Oct;29(5):326-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of nuclear appearance in pathologic recognition and delimitation of sessile serrated polyps of the colon: a karyometric study.
  • OBJECTIVE: To estimate the extent to which surgical pathologists can rely on abnormal nuclear appearance to recognize sessile serrated adenoma (SSP) and to define its extent.
  • STUDY DESIGN: Digitized images of nuclei of superficial crypt cells from SSPs, banal hyperplastic polyps (BHPs), tubular adenomas (TAs) and normal colonic mucosa (N) in surgical pathology specimens were analyzed for size, shape, area, optical density (summed and average) and 22 Markovian texture characteristics.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987813.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Khan MN, Moran BJ: Four percent of patients undergoing colorectal cancer surgery may have synchronous appendiceal neoplasia. Dis Colon Rectum; 2007 Nov;50(11):1856-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: An individual with colorectal cancer has a 3 percent risk of synchronous colonic neoplasia and further 2 to 3 percent risk of metachronous cancer, a risk that has prompted colonic surveillance.
  • The appendix has a similar mucosal pattern to the colon and it has been hypothesized that appendicular adenocarcinoma may account for 1 percent of all colorectal malignancies.
  • Data also were collected for patients who had right hemicolectomy for colonic carcinoma.
  • Seven of 169 appendices had abnormalities: 3 mucinous cystadenomas, 2 cystadenocarcinomas, 1 carcinoid tumor, and 1 villous adenoma.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763906.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Klenow S, Glei M, Haber B, Owen R, Pool-Zobel BL: Carob fibre compounds modulate parameters of cell growth differently in human HT29 colon adenocarcinoma cells than in LT97 colon adenoma cells. Food Chem Toxicol; 2008 Apr;46(4):1389-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carob fibre compounds modulate parameters of cell growth differently in human HT29 colon adenocarcinoma cells than in LT97 colon adenoma cells.
  • An extract of the Mediterranean carob (Ceratonia siliqua L.) pod (carob fibre extract), products formed after its fermentation by the gut flora and the major phenolic ingredient gallic acid (GA), were comparatively investigated for their influence on survival and growth parameters of colon adenocarcinoma HT29 cells and adenoma LT97 cells.
  • The differently modulated growth of human colon cell lines was more related to proliferation rates and impairment of DNA-synthesis than to H2O2 formation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Antineoplastic Agents, Phytogenic. Cell Division / drug effects. Colonic Neoplasms / pathology. Dietary Fiber / pharmacology. Fabaceae / chemistry

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950517.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Culture Media; 0 / DNA, Neoplasm; 0 / Phenols; 0 / Sulfoxides; 0 / Xylenes; BBX060AN9V / Hydrogen Peroxide; S2VDY878QD / xylenol orange
  •  go-up   go-down


14. Zapatka M, Zboralski D, Radacz Y, Böckmann M, Arnold C, Schöneck A, Hoppe S, Tannapfel A, Schmiegel W, Simon-Assmann P, Schwarte-Waldhoff I: Basement membrane component laminin-5 is a target of the tumor suppressor Smad4. Oncogene; 2007 Mar 1;26(10):1417-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor suppressor Smad4 is involved in carcinogenesis mainly of the pancreas and colon.
  • Herein, we report that in human colon and pancreatic tumor cells, Smad4 functions as a positive transcriptional regulator of all three genes encoding laminin-5.
  • [MeSH-major] Cell Adhesion Molecules / physiology. Colonic Neoplasms / metabolism. Genes, Tumor Suppressor. Pancreatic Neoplasms / metabolism. Smad4 Protein / physiology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma / metabolism. Basement Membrane / metabolism. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Humans. Signal Transduction. Transforming Growth Factor beta

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16953227.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; 0 / kalinin
  •  go-up   go-down


15. Fu K, Sano Y, Kato S, Fujii T, Iwasaki J, Sugito M, Ono M, Saito N, Yoshida S, Fujimori T: Hazards of endoscopic biopsy for flat adenoma before endoscopic mucosal resection. Dig Dis Sci; 2005 Jul;50(7):1324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hazards of endoscopic biopsy for flat adenoma before endoscopic mucosal resection.
  • [MeSH-major] Adenoma / pathology. Biopsy / adverse effects. Colonic Neoplasms / pathology. Colonoscopy / adverse effects. Intestinal Perforation / etiology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1992 Feb;87(2):161-7 [1734693.001]
  • [Cites] Am J Gastroenterol. 1994 Mar;89(3):449-50 [8122666.001]
  • [Cites] Gastrointest Endosc. 1995 Nov;42(5):475-9 [8566641.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):682-9 [10840300.001]
  • [Cites] J Am Coll Surg. 1994 Sep;179(3):333-7 [8069431.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):306-10 [11315890.001]
  • [Cites] Gastrointest Endosc. 1997 Nov;46(5):464-6 [9402126.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):258-9 [11474408.001]
  • [Cites] Gastrointest Endosc. 1994 Jul-Aug;40(4):485-9 [7926542.001]
  • [Cites] Dis Colon Rectum. 1991 Feb;34(2):132-5 [1993410.001]
  • [Cites] Surg Clin North Am. 1982 Oct;62(5):889-96 [6981859.001]
  • [Cites] Acta Chir Belg. 1993 Mar-Apr;93(2):60-2 [8470448.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1308-14 [8918445.001]
  • (PMID = 16047481.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Laos S, Baeckström D, Hansson GC: Inhibition of NF-kappaB activation and chemokine expression by the leukocyte glycoprotein, CD43, in colon cancer cells. Int J Oncol; 2006 Mar;28(3):695-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of NF-kappaB activation and chemokine expression by the leukocyte glycoprotein, CD43, in colon cancer cells.
  • It is frequently overexpressed in early colon adenomas, but not in normal colon epithelial cells.
  • To identify CD43 target genes, gene array analysis was performed using a tetracycline-inducible CD43 expression system in human colon adenocarcinoma SW480 cells.
  • [MeSH-minor] Active Transport, Cell Nucleus / drug effects. Blotting, Western. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Chemokine CCL2 / genetics. Chemokine CCL2 / metabolism. Chemokine CXCL1. Chemokines, CXC / genetics. Chemokines, CXC / metabolism. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Gene Expression Regulation, Neoplastic / genetics. Humans. I-kappa B Proteins / metabolism. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Interleukin-8 / genetics. Interleukin-8 / metabolism. PPAR gamma / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Time Factors. Transcription Factor RelA / genetics. Transcription Factor RelA / metabolism. Tumor Necrosis Factor-alpha / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465375.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / CCL2 protein, human; 0 / CXCL1 protein, human; 0 / Chemokine CCL2; 0 / Chemokine CXCL1; 0 / Chemokines; 0 / Chemokines, CXC; 0 / I-kappa B Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-8; 0 / NF-kappa B; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-kappaB inhibitor alpha
  •  go-up   go-down


17. Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA: Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer; 2010 Mar 15;116(6):1454-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center.
  • BACKGROUND: The ability of integrated positron emission tomography and computed axial tomography (PET-CT) to detect colonic pathology is not fully defined.
  • The purpose of this study was to assess the ability of PET-CT to detect colonic pathology and to determine the significance of ((18)F)2-fluoro-2-deoxyglucose ((18)F-FDG) activity noted incidentally in the colon on PET-CT.
  • Patients with history of colonic malignancy or colon surgery were excluded.
  • RESULTS: Fifty-eight patients had incidental colonic (18)F-FDG activity on PET (Group A) and 272 had none (Group B).
  • In Group B, 11.8% of patients were found to have significant colonic findings.
  • Lesions not detected by PET-CT included 4 colon cancers, 7 advanced adenomas, and 10 patients with colonic lymphoma.
  • For detecting colon cancer and adenomas 10 mm or more, the sensitivity, specificity, PPV, NPV, and accuracy of PET-CT were 72%, 90%, 45%, 96%, and 88%, respectively.
  • CONCLUSIONS: Incidental colonic activity detected by PET-CT warrants further evaluation with colonoscopy.
  • However, negative PET-CT does not rule out significant colonic pathology including colon cancer, advanced adenomas, or lymphoma.
  • [MeSH-major] Colon / radiography. Colon / radionuclide imaging. Colonic Neoplasms / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adenoma / diagnosis. Colonoscopy. Deoxyglucose. False Positive Reactions. Female. Humans. Incidental Findings. Lymphoma / diagnosis. Male. Middle Aged. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143447.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


18. Hodadoostan MK, Reza F, Elham M, Mohammad Alizade AH, Molaie M, Mashaiekhy R, Doagoo SZ, Moosavy M, Malek FN, Zali MR: Clinical and pathology characteristics of colorectal polyps in Iranian population. Asian Pac J Cancer Prev; 2010;11(2):557-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathology characteristics of colorectal polyps in Iranian population.
  • BACKGROUND AND AIM: Colon polyps are important lesions and a concern because of the potential for colorectal cancer, one of the most common causes of cancer-related deaths in Iran.
  • The distribution of polyps in the colon may affect the efficacy of screening modalities.
  • The aim of this study was to determine clinical and pathology characteristics of colorectal polyps in the Iranian population.
  • METHODS: This cross sectional survey covered 856 polypectomies in 716 patients, with anatomical distribution, size and histopathology of the polyps described in 2004-2009 in the educational hospital of Taleghani in Tehran.
  • RESULTS: Polyps were observed in 437 males and 279 females.
  • The distribution was 3.12 percent located in the rectum, 19.6 percent in the sigmoid colon, 24.4 percent in the descending colon, 13.9 percent in the transverse colon, and 29.6 percent in the cecum and ascending colon.
  • Some 77(9%) were non-neoplastic and 779 (91%) were neoplastic.
  • Adenomas were present in 727 (85%) cases, of these 411 (56%) were left-sided and 316 (44% ) were right-sided.
  • Of the total, 354 were advance polyp (>1cm, villous type, high grade dysplasia), 87(34%) being found in patients under 50 years of age and 149 (58.6 %) being right sided.
  • CONCLUSION: This study showed a significant number of adenomas and carcinomas to lie proximal to the splenic flexure.
  • Thus, it is expected that examination of the colon limited to the splenic flexure would miss 44% of such lesions.
  • In addition there were higher stages of dysplasia and malignancy in larger polyps.
  • [MeSH-major] Adenoma / pathology. Colon / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843151.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


19. Saini SD, Schoenfeld P, Vijan S: Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer. Gastroenterology; 2010 Jun;138(7):2292-9, 2299.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer.
  • BACKGROUND & AIMS: Guidelines recommend that patients with colon adenomas undergo periodic surveillance colonoscopy.
  • We modeled a cohort of 50-year-old patients with newly diagnosed adenomas, following them until death.
  • Results were most sensitive to the annual probability of advanced adenoma formation and the relative risk (RR) of advanced adenoma formation in high-risk versus low-risk patients.
  • Assuming that the probability of advanced adenoma formation was 1.3% per year (base: 0.5%), the ICER of the 3/5 strategy was <$50,000 per QALY gained if the RR of advanced adenoma formation was <2.4 (base: 3.9).
  • Aggressive surveillance can be expensive or even harmful; efforts should be made to improve risk models for colonic neoplasia.
  • [MeSH-major] Adenoma / prevention & control. Colonoscopy. Colorectal Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20226186.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Huang EH, Park JC, Appelman H, Weinberg AD, Banerjee M, Logsdon CD, Schmidt AM: Induction of inflammatory bowel disease accelerates adenoma formation in Min +/- mice. Surgery; 2006 Jun;139(6):782-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of inflammatory bowel disease accelerates adenoma formation in Min +/- mice.
  • (1) multiple intestinal neoplasia (Min) +/- mice, bearing a mutation in the adenomatous polyposis coli (APC) gene;.
  • The small bowel and colon of 170 IL-10 null mice, 31 Min +/- mice, and 120 Min +/-/IL-10 null mice were examined microscopically.
  • RESULTS: The number of flat adenomas was increased in the colons of the Min +/-/IL-10-/- mice, compared with the Min +/- mice (P = .0005).
  • CONCLUSIONS: Breeding the Min +/- genotype into the IL-10 -/- background increased the incidence of colonic adenomas.
  • These findings provide a novel system to dissect the pathways by which inflammatory mechanisms accelerate adenoma formation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782435.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA091975; United States / NCI NIH HHS / CA / R01 CA87677; United States / NIDDK NIH HHS / DK / R01 DK56067
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


21. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D, Jacobs ET: Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer Res; 2010 Feb 15;70(4):1496-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence.
  • No gene-level associations were observed for VDR, nor was any single SNP in VDR related to any metachronous adenoma after correction for multiple comparisons.
  • Haplotypes within linkage blocks of RXRA support an approximately 30% reduction in odds of metachronous neoplasia arising in the proximal colon among carriers of specific haplotypes, which was strongest (OR(proximal), 0.67; 95% CI, 0.52-0.86) for carriers of a CGGGCA haplotype (rs1805352, rs3132297, rs3132296, rs3118529, rs3118536, and rs7861779).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2006 Nov;27(11):1129-34 [16937379.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1706-16 [17087956.001]
  • [Cites] Genet Epidemiol. 2007 Jul;31(5):383-95 [17410554.001]
  • [Cites] J Clin Gastroenterol. 2007 Sep;41(8):731-46 [17700421.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] Gut. 2007 Nov;56(11):1557-63 [17604322.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] PLoS One. 2008;3(1):e1483 [18213391.001]
  • [Cites] Nutr Cancer. 2008;60(1):97-108 [18444141.001]
  • [Cites] Cell Mol Life Sci. 2008 May;65(10):1523-43 [18278436.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):586-93 [18470879.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):944-8 [18375961.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S98-112 [18844852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2958-69 [18990737.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):769-76 [19255064.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1170-80 [19403841.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2304-12 [10786699.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):3931-9 [11089522.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):369-87 [11470825.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):869-74 [11489753.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):607-14 [11552708.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1267-74 [11751444.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25313-22 [12000762.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):488-94 [12829024.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29954-62 [12771132.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7799-806 [14633706.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1502-8 [15342452.001]
  • [Cites] Int J Epidemiol. 1980 Sep;9(3):227-31 [7440046.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Endocrinology. 1994 Apr;134(4):1710-7 [8137734.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):623-32 [8564982.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S57-73 [9379138.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • [Cites] Hum Genet. 1998 Oct;103(4):462-9 [9856491.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):144-51 [16004730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2061-3 [16172209.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):898-915 [16126938.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):629-44 [16532393.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Anticancer Res. 2009 Sep;29(9):3511-36 [19667145.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):1030-4 [16936639.001]
  • (PMID = 20145122.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106269; United States / NCI NIH HHS / CA / CA023074-22S1; United States / NCI NIH HHS / CA / P50 CA095060-01; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / K07CA106269; United States / NCI NIH HHS / CA / CA95060; United States / NCI NIH HHS / CA / CA77145; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA095060-01; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / R01 CA123065; United States / NCI NIH HHS / CA / K07 CA106269-01A1; United States / NCI NIH HHS / CA / P30 CA023074-22S1; United States / NCI NIH HHS / CA / P01 CA041108-13; United States / NCI NIH HHS / CA / P01CA41108; United States / NCI NIH HHS / CA / CA041108-13; United States / NCI NIH HHS / CA / CA106269-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Retinoid X Receptor alpha
  • [Other-IDs] NLM/ NIHMS262521; NLM/ PMC3019606
  •  go-up   go-down


22. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, Rhee PL, Kim JJ, Rhee JC, Choi YH: Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev; 2007 Aug;16(8):1543-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is metabolic syndrome a risk factor for colorectal adenoma?
  • However, there is a lack of information about the relationship between metabolic syndrome and colorectal adenoma.
  • Therefore, we investigated whether metabolic syndrome is a risk factor for colorectal adenoma.
  • We classified a total of 2,531 subjects into the adenoma group (n = 731) and the control group (n = 1,800), including normal colonoscopic finding, nonpolyp benign lesions, or histologically confirmed hyperplastic polyp.
  • RESULTS: The prevalence for metabolic syndrome was 17% in the adenoma group and 11% in the control group.
  • On the multiple logistic regression analyses, metabolic syndrome was found to be associated with an increased risk of colorectal adenoma (odds ratio, 1.51; 95% confidence interval, 1.18-1.93).
  • Also, waist circumference among the individual components of metabolic syndrome was an independent risk factor for colorectal adenoma.
  • An increased risk for metabolic syndrome was more evident for proximal than distal colon, for multiple (>/=3), and for advanced adenoma in the adenoma group.
  • CONCLUSION: Metabolic syndrome was associated with colorectal adenoma.
  • Abdominal obesity of the individual components of metabolic syndrome was an important risk factor for colorectal adenoma.
  • [MeSH-major] Adenoma / epidemiology. Colonic Neoplasms / epidemiology. Metabolic Syndrome X / epidemiology. Rectal Neoplasms / epidemiology
  • [MeSH-minor] Adenoma, Villous / epidemiology. Age Factors. Alcohol Drinking / epidemiology. Body Weights and Measures. Colonic Polyps / epidemiology. Colonoscopy. Diabetes Mellitus / epidemiology. Female. Humans. Hyperlipidemias / epidemiology. Hyperplasia. Hypertension / epidemiology. Korea / epidemiology. Male. Mass Screening. Middle Aged. Obesity / epidemiology. Precancerous Conditions / epidemiology. Risk Factors. Sex Factors. Smoking / epidemiology

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684126.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Giaginis C, Georgiadou M, Dimakopoulou K, Tsourouflis G, Gatzidou E, Kouraklis G, Theocharis S: Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci; 2009 Feb;54(2):282-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.
  • Our aim was to examine the clinical significance of MCM-2 and MCM-5 protein expression in colon cancer and to evaluate the association with various clinicopathological characteristics and tumor proliferative capacity.
  • Immunohistochemical expression of MCM-2 and MCM-5 was performed on paraffin-embedded malignant tissue sections obtained from 96 patients with colon cancer.
  • MCM-2 and Ki-67 expression was significantly associated with the tumors' histological grade (P = 0.003), existence of nodular metastases (N) (P = 0.003 and P = 0.030, respectively), malignancy on adenoma (P = 0.029 and P = 0.024, respectively), and vascular invasion (P = 0.010 and P = 0.011, respectively).
  • The current data suggest that MCM-2 protein expression is significantly associated with important clinicopathological characteristics for patients' management, being correlated with the cell proliferation state in colon cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Colon / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Minichromosome Maintenance Complex Component 2

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO Rep. 2003 Jan;4(1):26-30 [12524516.001]
  • [Cites] J Pathol. 2003 Oct;201(2):187-97 [14517835.001]
  • [Cites] Annu Rev Biochem. 1999;68:649-86 [10872463.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1711-5 [17505513.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Histopathology. 2002 Jan;40(1):2-11 [11903593.001]
  • [Cites] Cell Tissue Kinet. 1987 Jul;20(4):387-91 [2448031.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] J Surg Oncol. 2003 Sep;84(1):24-30 [12949987.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):690-6 [11063933.001]
  • [Cites] J Cell Biol. 1988 Nov;107(5):1623-8 [2903166.001]
  • [Cites] Eur J Biochem. 2003 Mar;270(6):1089-101 [12631269.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1917-9 [12057556.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1434-8 [16885749.001]
  • [Cites] J Pathol. 1997 Dec;183(4):418-23 [9496258.001]
  • [Cites] BMJ. 1994 Oct 15;309(6960):996 [7950724.001]
  • [Cites] J Clin Pathol. 2005 May;58(5):525-34 [15858126.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Trends Cell Biol. 1997 Jan;7(1):9-10 [17708892.001]
  • [Cites] Annu Rev Biochem. 2002;71:333-74 [12045100.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):455-66 [16150117.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1081-5 [9740071.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1075-81 [11948116.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4259-66 [11709570.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9 [15899946.001]
  • [Cites] J Pathol. 2000 Apr;190(5):537-44 [10727979.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Curr Opin Cell Biol. 2006 Apr;18(2):130-6 [16495042.001]
  • [Cites] Pathobiology. 2001;69(3):150-8 [11872961.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):899-907 [16112007.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • (PMID = 18465232.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


24. Fujimori T, Fujii S, Saito N, Sugihara K: Pathological diagnosis of early colorectal carcinoma and its clinical implications. Digestion; 2009;79 Suppl 1:40-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma, Villous / pathology. Colon / pathology. Colonoscopy. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153489.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 50
  •  go-up   go-down


25. Van Slambrouck S, Grijelmo C, De Wever O, Bruyneel E, Emami S, Gespach C, Steelant WF: Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int J Oncol; 2007 Dec;31(6):1501-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.
  • Increased src tyrosine kinase expression and activity has been associated with colon cancer cell invasion and survival.
  • Several signaling pathways are involved in the oncogenic activation of src during the adenoma to carcinoma progression and cellular invasion.
  • In the present study, the synthetic ether lipid analog ET-18-OMe was shown to promote invasion of HCT-8/S11 colon cancer cells into collagen type I through the concomitant activation of src by phosphorylation at Tyr416 (5-30 min) in alpha1-integrin immunoprecipitates containing the integrin binding proteins talin and paxillin, as well as the phoshorylated and activated forms of focal adhesion kinase (FAK) at Tyr397 (a FAK kinase activation signal), Tyr576 and Tyr861.
  • These findings support the notion that the alpha1-integrin- and src-dependent signalosome is a relevant therapeutic target against tumor progression in colon cancer patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Crk-Associated Substrate Protein / physiology. Focal Adhesion Kinase 1 / physiology. Integrin alpha1 / physiology. JNK Mitogen-Activated Protein Kinases / physiology. MAP Kinase Signaling System / physiology. src-Family Kinases / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982677.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR16480
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Crk-Associated Substrate Protein; 0 / Integrin alpha1; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


26. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM: The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res; 2005 Dec 15;65(24):11486-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined whether this shift occurs in vitro in the human colon cancer cell line Caco-2 in association with the loss of terminal differentiation and apoptosis, or in vivo during the formation of colorectal adenomas in patients with familial adenomatous polyposis (FAP).
  • In FAP patients, 15-LOX-1 expression and activity were significantly down-regulated in adenomas (compared with paired nonneoplastic epithelial mucosa), whereas 5-LOX and 15-LOX-2 protein expressions and enzymatic activities were not.
  • We conducted a validation study with immunohistochemical testing in a second group of FAP patients; 15-LOX-1 expression was down-regulated in colorectal adenomas (compared with nonneoplastic epithelial mucosa) in 87% (13 of 15) of this group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Feb 11;467(2-3):341-7 [10675566.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 24;268(3):778-83 [10679282.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1136-42 [10904086.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6846-50 [11156377.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):497-503 [11212240.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4879-84 [11406566.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6307-12 [11522616.001]
  • [Cites] Anal Biochem. 2001 Oct 15;297(2):183-90 [11673886.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2721-7 [11980674.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):243-7 [12584173.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9968-73 [12909723.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6170-3 [14559799.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Jan;70(1):7-15 [14643174.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):111-22 [15165036.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28028-35 [15123685.001]
  • [Cites] J Biol Chem. 1990 Mar 25;265(9):5113-20 [2318885.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3288-93 [8205551.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21569-77 [9705287.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1985-95 [10506115.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • (PMID = 16357157.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA086970; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / K07 CA86970; United States / NCI NIH HHS / CA / P30 CA16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Linoleic Acids; 0 / RNA, Messenger; 5204-88-6 / 13-hydroxy-9,11-octadecadienoic acid; EC 1.13.11.33 / ALOX15B protein, human; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  • [Other-IDs] NLM/ NIHMS5001; NLM/ PMC1564070
  •  go-up   go-down


27. Kind of meat eaten may increase risk of colon polyps. Health News; 2006 Feb;12(2):11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kind of meat eaten may increase risk of colon polyps.
  • [MeSH-major] Adenoma / etiology. Colonic Neoplasms / etiology. Colonic Polyps / etiology. Meat / adverse effects

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16453938.001).
  • [ISSN] 1081-5880
  • [Journal-full-title] Health news (Waltham, Mass.)
  • [ISO-abbreviation] Health News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ: Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med; 2010;7(11):e1000370
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that different FIT assays and collection methods have been previously tested, three distinct FIT testing strategies were considered, on the basis of studies that have reported "low," "mid," and "high" test performance characteristics for detecting adenomas and CRC.
  • Adenoma and CRC prevalence rates were based on a recent systematic review whereas screening adherence, test performance, and CRC treatment costs were based on publicly available data.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Am J Gastroenterol. 2004 Jun;99(6):1141-4 [15180738.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):317-9 [15269308.001]
  • [Cites] Radiology. 2004 Sep;232(3):784-90 [15247435.001]
  • [Cites] Ann Intern Med. 2004 Sep 7;141(5):401-3 [15353432.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Ann Intern Med. 2005 Apr 19;142(8):635-50 [15838071.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):422-8 [16083699.001]
  • [Cites] CMAJ. 2005 Oct 11;173(8):877-81 [16217110.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] J Med Screen. 1999;6(3):119-23 [10572841.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):947-55 [11038030.001]
  • [Cites] Radiology. 2006 May;239(2):457-63 [16543590.001]
  • [Cites] Radiology. 2006 May;239(2):464-71 [16569789.001]
  • [Cites] Radiology. 2006 May;239(2):313-6 [16641348.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1863-72 [17079760.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1700-5 [17087932.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):96-102 [17241863.001]
  • [Cites] Ann Intern Med. 2007 Feb 20;146(4):244-55 [17310048.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):380-90 [17156139.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2213-21 [17455218.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2259-64 [17617203.001]
  • [Cites] N Engl J Med. 2007 Oct 4;357(14):1403-12 [17914041.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1357-67 [18033685.001]
  • [Cites] Med Decis Making. 2008 Jan-Feb;28(1):56-65 [18263561.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Apr;27(8):697-712 [18248653.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):82-90 [18482589.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Aug;6(8):912-917.e1 [18534918.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Ann Intern Med. 2008 Oct 7;149(7):441-50, W81 [18838724.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):659-69 [18838717.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):638-58 [18838718.001]
  • [Cites] Ann Intern Med. 2009 Jun 16;150(12):849-57, W152 [19528563.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Dec;7(12):1272-8 [19523536.001]
  • [Cites] Gut. 2010 Jan;59(1):62-8 [19671542.001]
  • [Cites] Ann Fam Med. 2010 Sep-Oct;8(5):397-401 [20843880.001]
  • [Cites] Eur J Cancer. 2001 Feb;37(3):398-401 [11239763.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):319-32 [11438266.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] J Clin Gastroenterol. 1992 Dec;15(4):347-51 [1294644.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Dis Colon Rectum. 1993 Dec;36(12):1126-31 [8253009.001]
  • [Cites] Health Econ. 1994 Mar-Apr;3(2):95-104 [8044216.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):42-4 [8653359.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1467-71 [8942774.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] Health Econ. 1998 Dec;7(8):723-40 [9890333.001]
  • [Cites] Endoscopy. 1999 Mar;31(3):227-31 [10344426.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1650-7 [10364039.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):96-104 [12118964.001]
  • [Cites] Am J Kidney Dis. 2002 Sep;40(3):611-22 [12200814.001]
  • [Cites] Value Health. 2003 Jan-Feb;6(1):9-17 [12535234.001]
  • [Cites] Int J Gastrointest Cancer. 2001;30(3):133-40 [12540025.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):413-20 [12588199.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] Ann Intern Med. 2003 Dec 16;139(12):959-65 [14678915.001]
  • [Cites] Chronic Dis Can. 2003 Fall;24(4):91-101 [14733758.001]
  • [Cites] Can J Gastroenterol. 2004 Feb;18(2):93-9 [14997217.001]
  • [Cites] Can J Gastroenterol. 2004 Apr;18(4):221-6 [15054498.001]
  • [ErratumIn] PLoS Med. 2012 Nov;9(11). doi: 10.1371/annotation/0fd49c83-2c6d-42b5-a8c1-45a0aaedaa77
  • (PMID = 21124887.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2990704
  •  go-up   go-down


29. Strum WB: Impact of adenoma size in distal colon on risk for advanced adenoma of the proximal colon. Dig Dis Sci; 2006 Nov;51(11):2064-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of adenoma size in distal colon on risk for advanced adenoma of the proximal colon.
  • Adenomas of the rectosigmoid colon are considered markers of risk for advanced adenomas of the proximal colon.
  • This study was designed to determine the risk for advanced adenomas in the proximal colon in patients from a large, homogeneous population with an advanced or nonadvanced adenoma of the distal colon.
  • We designed a prospective study of 7157 patients who were evaluated for neoplasia by flexible sigmoidoscopy and, when adenomas were found, by colonoscopy.
  • Adenomas were considered advanced if they were > or =10 mm in size or had villous or dysplastic features.
  • Ninety-seven patients had an advanced adenoma of the distal colon (Group A) and were compared with 183 patients who had a nonadvanced adenoma (Group B).
  • Seven patients (7.2%) in Group A had an advanced adenoma of the proximal colon, compared with four patients (2.2%) in Group B (P < 0.05, relative risk = 3.3).
  • When patients with adenomas of the distal colon >5 mm (Group C) were compared to patients with adenomas < or =5 mm (Group D), the prevalence of advanced adenomas of the proximal colon remained at 7% (10/143) for Group C but fell to 0.73% (1/137) for Group D (P = 0.011, relative risk = 9.6).
  • By expanding the criteria for risk from adenomas of the distal colon to include all adenomas >5 mm, the relative risk for advanced adenoma of the proximal colon was increased threefold.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Jan 2;336(1):8-12 [8970934.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):492-6 [9434214.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1501-4 [8194695.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):413-20 [12588199.001]
  • [Cites] N Engl J Med. 2002 Jan 3;346(1):40-4 [11778002.001]
  • [Cites] Ann Intern Med. 1998 Aug 15;129(4):273-8 [9729179.001]
  • [Cites] Gastrointest Endosc. 1996 Jan;43(1):25-8 [8903813.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] JAMA. 1999 May 5;281(17):1611-7 [10235154.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1167-74 [15057755.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):533-41 [9721149.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Ann Intern Med. 2003 Dec 16;139(12):959-65 [14678915.001]
  • [Cites] Dig Dis Sci. 2006 Nov;51(11):2048-52 [17072763.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 May;1(3):195-201 [15017491.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Mar;1(2):103-10 [15017502.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Dig Dis Sci. 2003 Dec;48(12):2278-83 [14714613.001]
  • (PMID = 17021962.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Wassenaar MJ, Biermasz NR, Pereira AM, van der Klaauw AA, Smit JW, Roelfsema F, van der Straaten T, Cazemier M, Hommes DW, Kroon HM, Kloppenburg M, Guchelaar HJ, Romijn JA: The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab; 2009 Dec;94(12):4671-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The presence of the d3GHR polymorphism was assessed in 86 acromegalic patients with long-term disease control and related to anthropometric parameters, cardiovascular risk factors, osteoarthritis, bone mineral density, colonic polyps and diverticulae, and dolichocolon.
  • Carriers of the d3GHR isoform showed increased prevalence of osteoarthritis, especially of the hip [adjusted odds ratio (OR), 5.2; 95% confidence interval (CI), 3.2-7.1], of adenomatous polyps (adjusted OR, 4.1; 95% CI, 2.4-5.6), and dolichocolon (adjusted OR, 3.2; 95% CI, 1.8-4.6).
  • Anthropometric parameters, cardiovascular risk factors, bone mineral density, and (non)vertebral fractures were not significantly different between patients with and without the d3GHR allele.
  • CONCLUSION: In patients with long-term cured acromegaly, the d3GHR polymorphism is associated with an increased prevalence of irreversible comorbidities such as osteoarthritis, dolichocolon, and adenomatous colonic polyps, but not with other comorbidities such as cardiovascular risk factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anthropometry. Bone Density / genetics. Bone Density / physiology. Cardiovascular Diseases / epidemiology. Cardiovascular Diseases / genetics. Cohort Studies. Colonic Diseases / epidemiology. Colonic Diseases / genetics. DNA / genetics. DNA / isolation & purification. Female. Gene Deletion. Genetic Predisposition to Disease. Human Growth Hormone / metabolism. Human Growth Hormone / physiology. Humans. Insulin-Like Growth Factor I / metabolism. Male. Middle Aged. Osteoarthritis / epidemiology. Osteoarthritis / genetics. Osteoarthritis / radiography. Osteoporosis / epidemiology. Osteoporosis / genetics. Risk Factors. Spinal Fractures / epidemiology. Spinal Fractures / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetics Home Reference. consumer health - GHR gene.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19864451.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Somatotropin; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9007-49-2 / DNA
  •  go-up   go-down


31. Jurek D, Fleckl E, Marian B: Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem Toxicol; 2005 Jan;43(1):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile acid induced gene expression in LT97 colonic adenoma cells.
  • LT97 human colonic adenoma cells reflecting early premalignant genotype and growth characteristics have been posed to tumor promoting bile acids in order to identify marker genes that permit identification of tumor promoters in vitro.
  • Physiologically relevant concentrations of desoxycholate (DOC) and chenodesoxycholate (CDC) upregulated expression of c-fos and COX-2 in a concentration- and time-dependent manner.
  • Transient induction of c-fos was seen with the non-promoting taurodesoxycholate (TDOC) as well as DOC, however extended induction at 3 h was only achieved by DOC and CDC reaching 3-6-fold as compared to the control.
  • Stimulation of COX-2 expression was completely specific for the tumor promoting analogs DOC and CDC.
  • Expression of VEGF was stimulated 4-5-fold in the tumor promoter (DOC and CDC) groups and about 2-fold in the non-promoting controls TDOC and GCDC.
  • At later times the tumor promoter specific difference was lost.
  • Our results show that all three genes are modulated in a tumor promoter dependent way and that their upregulation in LT97 adenoma cells can be used for in vitro testing of colon tumor promoters and chemopreventive compounds.
  • [MeSH-major] Adenoma / metabolism. Bile Acids and Salts / pharmacology. Biomarkers, Tumor / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / drug effects

  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582199.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-fos; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 005990WHZZ / Deoxycholic Acid; 0GEI24LG0J / Chenodeoxycholic Acid; 516-50-7 / Taurodeoxycholic Acid; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


32. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M: Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med; 2010 Sep 21;153(6):368-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LIMITATION: No pathways other than the traditional adenoma-carcinoma sequence were modeled.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Jun 1;115(11):2410-9 [19288570.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2862-70 [18759824.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1270-9 [15131787.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):386-95 [15507679.001]
  • [Cites] Cancer. 1979 May;43(5):1847-57 [445371.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):819-25 [7055790.001]
  • [Cites] Gut. 1982 Oct;23(10):835-42 [7117903.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):179-86 [4018911.001]
  • [Cites] Int J Cancer. 1986 Aug 15;38(2):173-6 [3733258.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1472-6 [3345499.001]
  • [Cites] Scand J Gastroenterol. 1989 Sep;24(7):799-806 [2799283.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Gut. 1992 Nov;33(11):1508-14 [1452076.001]
  • [Cites] Comput Biomed Res. 1999 Feb;32(1):13-33 [10066353.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):434-7 [10070942.001]
  • [Cites] Ann Surg. 1963 Feb;157:223-6 [14020146.001]
  • [Cites] Dis Colon Rectum. 1964 Jul-Aug;7:249-61 [14176135.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Am J Prev Med. 2005 Feb;28(2):208-14 [15710277.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):422-8 [16083699.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):277-83 [16342248.001]
  • [Cites] CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50 [16449183.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] BMC Cancer. 2006;6:136 [16723013.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):557-63 [10749911.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] JAMA. 2002 May 8;287(18):2428-9 [11988064.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1786-92 [12454834.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):47-53 [12777192.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1863-72 [17079760.001]
  • [Cites] Ann Intern Med. 2006 Dec 19;145(12):880-6 [17179057.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Endoscopy. 2007 Feb;39(2):168-73 [17327977.001]
  • [Cites] Am J Manag Care. 2007 Jul;13(7):393-400 [17620034.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2259-64 [17617203.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):630-41 [18445825.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1623-30 [18628413.001]
  • [Cites] Ann Intern Med. 2008 Oct 7;149(7):441-50, W81 [18838724.001]
  • [Cites] Ann Intern Med. 2008 Oct 7;149(7):509-10 [18838731.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] Ann Intern Med. 2009 Jun 16;150(12):849-57, W152 [19528563.001]
  • (PMID = 20855801.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA115953; United States / NCI NIH HHS / CA / U01 CA097426; United States / NCI NIH HHS / CA / P30 CA008748; United States / PHS HHS / / HHSP233200700196P; United States / PHS HHS / / HHSP233200700350P; United States / NCI NIH HHS / CA / U01-CA-115953; United States / NCI NIH HHS / CA / U01-CA-088204; United States / PHS HHS / / HHSP233200700123P; United States / NCI NIH HHS / CA / U01 CA088204; United States / NCI NIH HHS / CA / U01-CA-097426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS438539; NLM/ PMC3578600
  •  go-up   go-down


33. Emmons KM, McBride CM, Puleo E, Pollak KI, Clipp E, Kuntz K, Marcus BH, Napolitano M, Onken J, Farraye F, Fletcher R: Project PREVENT: a randomized trial to reduce multiple behavioral risk factors for colon cancer. Cancer Epidemiol Biomarkers Prev; 2005 Jun;14(6):1453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Project PREVENT: a randomized trial to reduce multiple behavioral risk factors for colon cancer.
  • BACKGROUND: This report examines the outcome data for Project PREVENT, a two-site randomized control trial designed to reduce behavioral risk factors for colorectal cancer among individuals who have been diagnosed with adenomatous colon polyps.
  • METHODS: The study sample included 1,247 patients with recent diagnosis of adenomatous colorectal polyps.
  • [MeSH-major] Colonic Neoplasms / prevention & control. Diet. Health Behavior
  • [MeSH-minor] Adenomatous Polyposis Coli / complications. Adult. Aged. Alcohol Drinking. Exercise. Female. Humans. Male. Middle Aged. Risk Factors. Smoking. Telephone

  • MedlinePlus Health Information. consumer health - Healthy Aging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941955.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R01 CA74000-04
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


34. Lynch PM: Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer; 2008;7(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial Adenomatous Polyposis (FAP) is a model for the adenoma-carcinoma sequence in several respects.
  • Early prevention trials mainly utilized micronutrients and were largely unsuccessful in preventing or causing regression of adenomas.
  • A new era was ushered in by the recognition that antiarthritic doses of a nonsteroidal anti-inflammatory agent (NSAID), sulindac, could actually induce regression of colorectal adenomas in patients with FAP.
  • Follow-up studies showed positive but variable long-term efficacy for colorectal adenomas, but sulindac appears to lack significant benefit in regressing duodenal adenomas or preventing initial occurrence of adenomas in APC mutation carriers.
  • Celecoxib has shown benefit in regressing colorectal adenomas and appears to have some duodenal activity as well.
  • However, the entire field of NSAID research in chemoprevention is undergoing reexamination in light of recent demonstration of cardiovascular toxicity in nonfamilial or sporadic adenoma prevention trials.
  • FAP will undoubtedly continue to have a lead role in the testing of new agents, both in the interest of FAP management as such, and in anticipation of trials in nonfamilial adenomas, a problem with even greater societal impact.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Chemoprevention / methods. Colorectal Neoplasms / genetics. Colorectal Neoplasms / prevention & control
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents. Ascorbic Acid / therapeutic use. Celecoxib. Clinical Trials as Topic. Curcumin / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Drug Therapy, Combination. Eflornithine / therapeutic use. Humans. Lactones / therapeutic use. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use. Sulfones / therapeutic use. Sulindac / therapeutic use. Vitamins / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. Eflornithine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1983 Sep;24(1):83-7 [6887943.001]
  • [Cites] Lancet. 1994 Jan 15;343(8890):180 [7904031.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1998-2002 [14627347.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Lancet. 1995 Apr 1;345(8953):855-6 [7898240.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):1035-8 [16757216.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Natl Cancer Inst. 1989 Sep 6;81(17):1290-7 [2549261.001]
  • [Cites] Gastroenterology. 1991 Sep;101(3):635-9 [1650315.001]
  • [Cites] Int J Colorectal Dis. 1993 Mar;8(1):13-7 [8388011.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):251-7 [16460482.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):14-8 [9112144.001]
  • [Cites] Hepatogastroenterology. 2002 Sep-Oct;49(47):1259-61 [12239919.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1674-82 [17087947.001]
  • [Cites] Dis Colon Rectum. 2001 Aug;44(8):1090-7; discussion 1097-9 [11535846.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1434-9 [7049351.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Fam Cancer. 2006;5(3):289-94; discussion 295-6 [16998675.001]
  • (PMID = 17680350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Sulfones; 0 / Vitamins; 0QTW8Z7MCR / rofecoxib; 184SNS8VUH / Sulindac; IT942ZTH98 / Curcumin; JCX84Q7J1L / Celecoxib; PQ6CK8PD0R / Ascorbic Acid; ZQN1G5V6SR / Eflornithine
  •  go-up   go-down


35. Ross SA, Finley JW, Milner JA: Allyl sulfur compounds from garlic modulate aberrant crypt formation. J Nutr; 2006 Mar;136(3 Suppl):852S-854S
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Garlic's sulfur components have been reported to suppress experimentally induced tumor incidence in several organs, including the colon.
  • Studies in humans also suggest that dietary garlic constituents reduce the risk of colorectal adenomatous polyps, which are considered precursors to colon cancer.
  • Aberrant crypt foci (ACF) are proposed to be early preneoplastic lesions of adenoma-carcinoma in humans and chemically induced colon cancer in rodents.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Colonic Neoplasms / prevention & control. Garlic. Plant Extracts / therapeutic use. Precancerous Conditions / prevention & control
  • [MeSH-minor] Adenoma / prevention & control. Animals. Disease Models, Animal. Rodentia. Sulfinic Acids / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484579.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Plant Extracts; 0 / Sulfinic Acids
  • [Number-of-references] 24
  •  go-up   go-down


36. Nusko G, Hahn EG, Mansmann U: Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence. Scand J Gastroenterol; 2009;44(6):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence.
  • OBJECTIVE: Because of the high recurrence rates of colorectal adenomas, regular surveillance by colonoscopy has been recommended, but there is still a dearth of information on the long-term results of follow-up colonoscopy after polypectomy.
  • The aims of this study were to determine the differences between initial adenomas and metachronous lesions, to evaluate the effect of long-term surveillance and to describe the hypothetical origin of the colorectal adenoma-carcinoma sequence.
  • MATERIAL AND METHODS: Between 1978 and 2003 a total of 1091 patients undergoing periodic surveillance examinations were prospectively documented at the Erlangen Registry of Colorectal Polyps.
  • Statistical analysis using chi(2) testing of adenoma characteristics found in four subsequent recurrence periods was carried out, and the relative risk (RR) for the development of metachronous adenomas of advanced pathology was calculated.
  • RESULTS: In comparison with the initial findings, metachronous adenomas are generally significantly smaller lesions (p<0.00001), usually tubular in shape (p<0.00001) and bearing high-grade dysplasia less often (p<0.00001) and are usually located in the right colon (p<0.00001).
  • These differences are found between the initial and four subsequent generations of metachronous adenomas.
  • The number of synchronous adenomas is reduced only in the first recurrence (p<0.001); in the further generations equal proportions of multiplicity are found, as in the baseline examination.
  • Patients with adenomas of advanced pathology, i.e. large, tubulovillous or villous adenomas at baseline, have a significantly higher risk for large (RR 2.73; 95% CI 1.77-4.20), tubulovillous or villous (RR 1.55; 95% CI 1.06-2.25) or multiple (RR 2.45; 95% CI 1.83-3.29) metachronous adenomas at the first recurrence.
  • CONCLUSIONS: Metachronous adenomas show the uniform characteristics of being small tubular lesions rarely bearing high-grade dysplasia, usually located in the right colon.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277927.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


37. Salemis NS, Nisotakis K, Nazos K, Stavrinou P, Tsohataridis E: Perforated appendix and periappendicular abscess within an inguinal hernia. Hernia; 2006 Dec;10(6):528-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology revealed the presence of a villous adenoma near the base of the appendix.

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hernia. 2007 Jun;11(3):289-90 [17429715.001]
  • [Cites] Dis Colon Rectum. 1972 Nov-Dec;15(6):464-5 [4645616.001]
  • [Cites] Surgery. 1967 Feb;61(2):236-8 [6016974.001]
  • [Cites] Singapore Med J. 2005 Aug;46(8):424-5 [16049614.001]
  • [Cites] Br J Clin Pract. 1990 Nov;44(11):494-5 [2282304.001]
  • [Cites] J Comput Assist Tomogr. 2000 Nov-Dec;24(6):884-6 [11105705.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92 (4):700-2 [9128329.001]
  • [Cites] Hernia. 2003 Jun;7(2):89-91 [12820031.001]
  • [Cites] Hernia. 2003 Mar;7(1):50-1 [12612800.001]
  • [Cites] Hernia. 2004 May;8(2):164-5 [14625701.001]
  • [Cites] Surg Gynecol Obstet. 1953 Nov;97(5):643-52 [13113546.001]
  • [Cites] East Afr Med J. 2004 Sep;81(9):490-1 [15626061.001]
  • [Cites] Rev Esp Enferm Dig. 2002 Sep;94(9):537-43 [12587234.001]
  • [Cites] Ann R Coll Surg Engl. 1982 Mar;64(2):121-2 [7065599.001]
  • [Cites] Br J Surg. 1977 Aug;64(8):593-5 [890285.001]
  • [Cites] Am Surg. 2001 Jul;67(7):628-9 [11450774.001]
  • [Cites] South Med J. 2001 May;94(5):496-8 [11372799.001]
  • (PMID = 16932844.001).
  • [ISSN] 1265-4906
  • [Journal-full-title] Hernia : the journal of hernias and abdominal wall surgery
  • [ISO-abbreviation] Hernia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer; 2008 Jun 1;122(11):2429-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.
  • However, it remains controversial whether methylation of specific CpG sequences within MGMT promoter leads to loss of its protein expression, and if MGMT methylation correlates with G to A transition mutations in KRAS.
  • Two methylation sensitive regions (Mp and Eh region) of MGMT promoter were investigated in 593 specimens of colorectal tissue: 233 CRCs, 104 adenomatous polyps (AP), 220 normal colonic mucosa from CRC patients (N-C) and 36 normal colonic mucosa specimens obtained from subjects without colorectal neoplasia (N-N) by combined bisulfite restriction analysis (COBRA).
  • The region-specific methylation data were compared to the MGMT protein expression, spectrum of KRAS mutations and other clinical features.
  • Extensive (including both Mp and Eh) and partial (either Mp or Eh) MGMT methylation were found in 24.5% and 11.6% of CRCs, 3.8% and 27.9% of APs, 0.5% and 7.7% of C-Ns and 2.8% and 2.8% of N-Ns, respectively.
  • Our data suggest that MGMT methylation may evolve and spread throughout the promoter in a stepwise manner as the colonic epithelial cells progress through the classical-adenoma-cancer multistep cascade.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5306-12 [14614014.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4842-8 [12941804.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6119-29 [2205376.001]
  • [Cites] Nucleic Acids Res. 1991 Nov 25;19(22):6163-7 [1956775.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6471-5 [1423294.001]
  • [Cites] Biochim Biophys Acta. 1994 Mar 1;1217(2):141-6 [8110828.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5612-9 [9271436.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3672-7 [9288770.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2029-33 [10232580.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):223-31 [15719030.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):206-11 [15819717.001]
  • [Cites] Gut. 2005 Jun;54(6):797-802 [15888787.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1073-7 [17960246.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):827-30 [11221863.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1300-9 [11729109.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2760-8 [11753949.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1166-70 [11861399.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):626-33 [12612901.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8835-44 [14647440.001]
  • (PMID = 18240147.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA98572; United States / NCI NIH HHS / CA / R01 CA098572; United States / NCI NIH HHS / CA / R01-CA72851; United States / NCI NIH HHS / CA / R01 CA072851-13; United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA098572-05; United States / NCI NIH HHS / CA / CA098572-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS187517; NLM/ PMC2851179
  •  go-up   go-down


39. Barry EL, Baron JA, Grau MV, Wallace K, Haile RW: K-ras mutations in incident sporadic colorectal adenomas. Cancer; 2006 Mar 1;106(5):1036-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras mutations in incident sporadic colorectal adenomas.
  • BACKGROUND: Although K-ras is the most frequently mutated protooncogene in colorectal carcinoma, the specific role and timing of K-ras mutations in colorectal carcinogenesis remains controversial.
  • In the current study, the authors investigated associations with K-ras mutation in incident sporadic colorectal adenomas that occurred during a chemoprevention trial of calcium supplementation.
  • METHODS: K-ras genotyping was performed on 303 colorectal adenomas that were removed from 207 participants during the follow-up phase of the Calcium Polyp Prevention Study.
  • RESULTS: The adenomas analyzed had a mean estimated size of 0.5 cm, and 3.0% were identified with mutations (95% confidence interval [95% CI], 1.3-4.4%).
  • These mutations were more common in larger adenomas (risk ratio [RR], 12.7 for tumors that measured > 0.5 cm vs. < or = 0.5 cm; 95% CI, 2.7-59.7), in adenomas with more advanced histology (RR, 20.6 for tubulovillous/villous vs. tubular; 95% CI, 4.4-96.0), and in adenomas that were located in the rectum compared with the colon (RR, 8.4; 95% CI, 2.3-30.5).
  • CONCLUSIONS: Compared with previous studies, the current analysis was novel, because it focused on incident adenomas that were diagnosed within a few years of a previous "clean" colonoscopy.
  • The results provided evidence for a very low rate of K-ras mutation among these small, early adenomas and strong support for a role of K-ras mutations in adenoma progression.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456810.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA046927; United States / NCI NIH HHS / CA / CA-046927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


40. Josemanders DF, Spillenaar Bilgen EJ, van Sorge AA, Wahab PJ, de Vries RA: Colonic explosion during endoscopic polypectomy: avoidable complication or bad luck? Endoscopy; 2006 Sep;38(9):943-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic explosion during endoscopic polypectomy: avoidable complication or bad luck?
  • We were confronted recently by an intraluminal colonic explosion during a colonic polypectomy procedure using snare loop electrocautery, probably caused by the presence of hydrogen and/or methane in combustible concentrations.
  • Our patient needed immediate surgery, when several lacerations were found in the colon: a right hemicolectomy and a partial sigmoid resection with primary anastomoses were performed.
  • Colonic bacteria, rests of fecal fluids, certain cleansing solutions, and oxygen insufflation are the main factors involved in cases of colonic explosion.
  • [MeSH-major] Adenoma / surgery. Cecal Neoplasms / surgery. Colonic Neoplasms / surgery. Colonoscopy. Electrocoagulation / adverse effects
  • [MeSH-minor] Aged. Colectomy. Colon / injuries. Colon, Sigmoid / pathology. Humans. Intraoperative Complications / etiology. Lacerations / etiology. Male

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2007 Mar;39(3):257 [17385112.001]
  • [CommentIn] Endoscopy. 2007 Mar;39(3):258 [17385113.001]
  • (PMID = 17019761.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Kim SE, Shim KN, Jung SA, Yoo K, Moon IH: An association between obesity and the prevalence of colonic adenoma according to age and gender. J Gastroenterol; 2007 Aug;42(8):616-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An association between obesity and the prevalence of colonic adenoma according to age and gender.
  • BACKGROUND: Epidemiologic data on obesity as a risk factor for colonic adenoma with respect to gender have not yet been confirmed.
  • Here, we aimed to compare the prevalence of colonic adenoma and of advanced polyps in age-stratified men and women at baseline, to examine the role of body mass index (BMI) on colonic adenoma risk according to age and gender, and to examine the influence of menopausal status.
  • BMI was assessed, and histology, size, and location of the adenoma were examined for each patient.
  • RESULTS: A significant increase in the prevalence of colonic adenoma and of advanced polyps was found to occur with age (P for trend < 0.01).
  • The prevalences of adenoma and advanced polyps were higher in men in most age groups (P < 0.01), but no significant difference in prevalences was observed between genderes in patients 70 years of age or older.
  • Moreover, a positive association between BMI and the prevalence of colonic adenoma and advanced polyps was shown in relatively young individuals of both gender (men in their thirties, P < 0.05; women in their forties, P < 0.05), and premenopausal women according to hormonal status (P = 0.01).
  • CONCLUSIONS: Our data suggest that obesity increases the risk of colonic adenoma in relatively young people and in premenopausal women subject to estrogen effects.
  • [MeSH-major] Adenoma / epidemiology. Colonic Neoplasms / epidemiology. Obesity / complications
  • [MeSH-minor] Adult. Age Factors. Aged. Biopsy. Body Mass Index. Colonic Polyps / epidemiology. Colonic Polyps / etiology. Colonic Polyps / pathology. Colonoscopy. Female. Humans. Korea / epidemiology. Male. Menopause. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Gut. 2002 Aug;51(2):147 [12117867.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):882-932 [12198715.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):346-9 [11487263.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):75-84 [12708728.001]
  • [Cites] Gut. 2004 Jan;53(1):156 [14684597.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):441-6 [9794177.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1212-8 [15894674.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):172-6 [8427777.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Cancer Causes Control. 1995 Mar;6(2):164-79 [7749056.001]
  • [Cites] Ann Intern Med. 1998 May 1;128(9):705-12 [9556463.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):779-84 [8896888.001]
  • [Cites] Gut. 2002 Aug;51(2):191-4 [12117878.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):443-7 [10794491.001]
  • [Cites] Am J Epidemiol. 2000 Nov 1;152(9):847-54 [11085396.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1062-7 [16234822.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):137-44 [8419236.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 6;83(5):359-61 [1995919.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):670-80 [9554606.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1799-805 [11734596.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):581-9 [15280637.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • (PMID = 17701124.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Cha JM, Lee JI, Joo KR, Jung SW, Shin HP: A prospective randomized study on computed virtual chromoendoscopy versus conventional colonoscopy for the detection of small colorectal adenomas. Dig Dis Sci; 2010 Aug;55(8):2357-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomized study on computed virtual chromoendoscopy versus conventional colonoscopy for the detection of small colorectal adenomas.
  • BACKGROUND: Colonoscopy is considered to be the standard diagnostic test for detecting colonic neoplasia, particularly for small lesions.
  • However, recent publications have suggested that 15-27% of small adenomas might be missed during conventional colonoscopy.
  • AIMS: To determine whether computed virtual chromoendoscopy (CVC) can improve the detection of small adenomas as compared to conventional colonoscopy.
  • METHODS: We examined 135 consecutive patients by total colonoscopy and 128 patients were randomized to compare white-light colonoscopy (65 patients) and CVC-mode colonoscopy (63 patients) after the exclusion of seven patients because of poor bowel preparation (n = 4) or other causes (one sigmoid colon cancer, two intestinal tuberculosis).
  • The groups did not differ in the number of patients with all polyps, adenomas, or hyperplastic polyps.
  • In the patients with adenomas, however, there was a significant difference in the detection rate for the patients with small adenomas less than 5 mm in size (P = 0.006).
  • CONCLUSIONS: Colonoscopy with the CVC mode identified more patients with small colorectal adenomas than conventional white-light colonoscopy.
  • Therefore, CVC might be a supplementary tool aiding the colonoscopist in the detection of small adenomas; however, further studies will need to demonstrate whether these results are reproducible across patients in varied clinical settings.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis. Endoscopy, Gastrointestinal / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2004 Dec;36(12):1094-8 [15578301.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1628-38 [17694415.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):378-84 [15758907.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):17-23 [8978337.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):349-54 [16527699.001]
  • [Cites] Endoscopy. 2001 Dec;33(12):1001-6 [11740641.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] J Clin Pathol. 1994 Oct;47(10):880-5 [7962600.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):562-9 [18070234.001]
  • [Cites] Gut. 2008 Jan;57(1):59-64 [17681999.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Cancer. 1963 Jun;16:751-64 [13928507.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1247-56 [15131784.001]
  • [Cites] Rev Gastroenterol Disord. 2006 Fall;6(4):209-20 [17224893.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):333-8 [12196768.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] J Clin Pathol. 1968 Nov;21(6):735-43 [5717544.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):42-7 [17631129.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):594-8 [17611913.001]
  • [Cites] Hepatogastroenterology. 2007 Dec;54(80):2240-2 [18265641.001]
  • [Cites] Gastrointest Endosc. 1993 Jul-Aug;39(4):592-3 [8365620.001]
  • [Cites] Am J Gastroenterol. 2007 Apr;102(4):856-61 [17222317.001]
  • [Cites] Gut. 2004 Mar;53(3):376-80 [14960519.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1259-64 [16996804.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):385-91 [15758908.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):80-3 [17252465.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:845-9 [4851945.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Dec;23(12):1810-5 [19032454.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):564-6 [1985054.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • (PMID = 19834809.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Tao S, Lu Q, Jiang B: [The clinical significance of colorectal flat lesions under endoscopy]. Zhonghua Yi Xue Za Zhi; 2007 May 29;87(20):1417-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify flat lesion in colon and rectum with combination of magnifying endoscope and mucosa staining technique ad to compare the differences between the protruded and flat colorectal lesions.
  • (1) A total of 1472 adenoma cases were found; 154 (10.46%) of which were of the flat type. (2) The average size of flat adenoma was (17 +/- 14) mm, significantly smaller than that of polypoid adenoma [(29 +/- 9) mm, P < 0.05)]. (3) The incidence of colorectal tumor in the left colon was 82.35% (140/170) in the flat type tumor, significantly higher than that in the protruded type tumors (79.59%, 1630/2048, P = 0.013). (4) The incidence rates of tubular adenoma, tubulo-villous adenoma, villous adenoma, and cancer were 51.34%, 4.25%, 8.79%, and 35.65% respectively in the protruded type tumor, and were 55.55%, 17.06%, 17.64%, and 9.43% respectively.
  • CONCLUSION: The detection rates of moderate and severe dysplasia and early colorectal cancer in the flat adenomas are higher than in the protruded adenoma.
  • Of higher malignancy grade, flat adenomatous lesions are more likely to be carcinomatous compared with the protruded adenomatous lesions.
  • [MeSH-major] Colon / pathology. Colonoscopy / methods. Intestinal Mucosa / pathology. Rectum / pathology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / epidemiology. Adenomatous Polyposis Coli / diagnosis. Adenomatous Polyposis Coli / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. China / epidemiology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Diagnosis, Differential. Humans. Incidence. Middle Aged

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785067.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Al-Thihli K, Palma L, Marcus V, Cesari M, Kushner YB, Barkun A, Foulkes WD: A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol; 2009 Mar;6(3):184-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 73-year-old white man was referred to a cancer genetics clinic for evaluation of a approximately 20-year history of mixed upper and lower gastrointestinal polyposis, including hyperplastic, inflammatory and adenomatous polyps, colonic ganglioneuromas, and associated diffuse, esophageal glycogenic acanthosis.
  • Multiple hyperplastic polyps and small, sessile polyps were also observed in the gastrectomy specimen.
  • [MeSH-major] Carcinoma / etiology. Gastrointestinal Diseases / etiology. Hamartoma Syndrome, Multiple / complications. Polyps / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190598.001).
  • [ISSN] 1743-4386
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


45. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, Diamandis EP, Xynopoulos D, Ardavanis A, Arnogiannaki N, Scorilas A: Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost; 2009 Apr;101(4):741-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we examined for the first time, the prognostic value of KLK7 mRNA expression, using a semi-quantitative RT-PCR method, in 105 colorectal cancer tissues for 54 of which, paired normal colonic mucosa were available.
  • Furthermore, we analysed the expression of KLK7 in 10 adenomas, in 18 biopsies of inflamed colon mucosa, as well as in 22 human cancer cell lines of various origin, four of them being of colon.
  • A defined number of colon cancer samples were also examined by immunohistochemistry.
  • In addition, selected colon cancer samples highly expressing KLK7 gene, showed intense immunohistochemical staining for KLK7, enhancing RT-PCR results.
  • Present data suggest that KLK7 gene is up-regulated in colon cancer and its expression predicts poor prognosis for colon cancer patients.
  • [MeSH-major] Adenoma / enzymology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / enzymology. Kallikreins / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350120.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


46. Brosens LA, Keller JJ, Pohjola L, Haglund C, Morsink FH, Iacobuzio-Donahue C, Goggins M, Giardiello FM, Ristimäki A, Offerhaus GJ: Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther; 2008 Mar;7(3):424-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
  • To investigate expression of HuR in the colorectal adenoma-carcinoma sequence, we examined expression of HuR in colorectal mucosa of patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer with correlation to COX-2 expression.
  • RESULTS: Cytoplasmic HuR staining was found in the epithelium of 10% of normal mucosa, 14.3% of adenomas and 88.9% of adenocarcinomas from FAP patients (p < 0.01) and in 68.8% of sporadic colorectal carcinomas.
  • High epithelial COX-2 immunostaining was observed in 10% of normal, 8% of adenomas and all adenocarcinomas from FAP patients (p < 0.01) and in 69.5% of sporadic colorectal carcinomas.
  • Positive cytoplasmic HuR immunostaining correlated with high COX-2 immunoreactivity in colon mucosa of FAP patients (p < 0.01) and in sporadic colorectal carcinomas. (p = 0.016) MATERIALS AND METHODS: HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C).
  • CONCLUSIONS: HuR is increasingly expressed in the cytoplasmic epithelial compartment in consecutive stages of the adenoma-carcinoma sequence in FAP.
  • Also, COX-2 levels correlate with cytoplasmic expression of HuR in colonic epithelium of FAP patients and in sporadic colorectal cancer specimens.
  • The role of cytoplasmic expression of HuR as a biomarker for progression of adenomas in FAP needs further study.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Antigens, Surface / genetics. RNA-Binding Proteins / genetics
  • [MeSH-minor] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. Cyclooxygenase 2 / genetics. Cytoplasm / physiology. ELAV Proteins. ELAV-Like Protein 1. Epithelial Cells / enzymology. Epithelial Cells / pathology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Intestinal Mucosa / pathology. Phosphoproteins / metabolism

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Mar;7(3):428-9 [18285701.001]
  • (PMID = 18094611.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 53801; United States / NCI NIH HHS / CA / CA51085; United States / NCI NIH HHS / CA / CA63721; United States / NCI NIH HHS / CA / P50 CA 93-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


47. Tsibouris P, Kalantzis C, Apostolopoulos P, Mavrogianni P, Alexandrakis G, Kalantzis N: Patients with selective vagotomy are at high risk to develop a significant polyp of the colon. J Clin Gastroenterol; 2009 Jul;43(6):599-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with selective vagotomy are at high risk to develop a significant polyp of the colon.
  • [MeSH-major] Adenoma / epidemiology. Colonic Neoplasms / epidemiology. Colonic Polyps / epidemiology. Vagotomy / adverse effects

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19247204.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


48. Armbrust T, Sobotta M, Füzesi L, Grabbe E, Ramadori G: Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases. Eur J Gastroenterol Hepatol; 2007 Nov;19(11):988-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
  • Two patients had a complete suppression of the primary, two patients had an adenoma at the former site of the primary.
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / pathology. Aged. Colon / pathology. Colonic Polyps / drug therapy. Colonic Polyps / pathology. Colonic Polyps / surgery. Colonoscopy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049169.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


49. Harada K, Higaki S, Amano A, Hashimoto K, Hashimoto S, Gondo T, Sakaida I: A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon. Oncol Rep; 2007 Jun;17(6):1353-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon.
  • The histogenesis of depressed adenoma of the colon has not been sufficiently investigated.
  • Pericryptal myofibroblasts are stromal cells expressing smooth muscle actin, and are involved in the differentiation and multiplication of epithelial cells in the colonic epithelium.
  • COX-2 has been reported to be involved in the development of colon adenoma.
  • We studied the histogenesis of depressed adenoma of the colon by examining the relationship between the presence of pericryptal myofibroblasts and COX-2 expression.
  • Twenty-one depressed adenomas of the colon that had been resected endoscopically between June 1998 and May 2003 (mild-moderate atypia; mean diameter, 6.7 mm) and 23 elevated adenomas that had been resected endoscopically in 2003 (mild-moderate atypia; mean diameter, 11.7 mm), were studied.
  • Eighteen (78.3%) of the 23 elevated adenomas and six (28.6%) of the 21 depressed adenomas were positive for pericryptal myofibroblasts immunohistochemically, showing a significant difference (P<0.001).
  • Seventeen elevated adenomas (73.9%) and eight depressed adenomas (38.1%) were positive for COX-2 expression (P=0.016).
  • The histogenesis of depressed adenomas differs from that of elevated adenomas.
  • Our results suggest that a low number of pericryptal myofibroblasts and a low COX-2 expression are associated with depressed adenomas.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Cyclooxygenase 2 / metabolism. Fibroblasts / pathology. Membrane Proteins / metabolism. Myoblasts / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487390.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


50. Elitsur Y, Teitelbaum JE, Rewalt M, Nowicki M: Clinical and endoscopic data in juvenile polyposis syndrome in preadolescent children: a multicenter experience from the United States. J Clin Gastroenterol; 2009 Sep;43(8):734-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Family history of colon cancer was noted in 28% of children.
  • A total of 366 polyps were removed, of which 90.5% were pedunculated and 9.5% were sessile.
  • Polyps were evenly distributed throughout the colon.
  • Most of the polyps (99.2%) had benign histology (inflammatory changes) and 3 (0.8%) involved focal adenomatous changes.
  • No adenocarcinoma was identified in any of the 366 polyps.
  • CONCLUSIONS: Colonic polyps in JPS are rarely malignant during the pediatric age period.
  • Our data suggest that the recommended colonic surveillance in children should be modified.
  • [MeSH-major] Colonic Polyps
  • [MeSH-minor] Adenoma / complications. Adenoma / pathology. Child. Colon / pathology. Colonic Neoplasms / complications. Colonic Neoplasms / pathology. Colonoscopy. Endoscopy. Female. Gastrointestinal Hemorrhage / epidemiology. Gastrointestinal Hemorrhage / pathology. Humans. Male. Precancerous Conditions / complications. Precancerous Conditions / pathology. Syndrome. United States

  • Genetic Alliance. consumer health - Juvenile polyposis syndrome.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407664.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


51. Rutter CM, Savarino JE: An evidence-based microsimulation model for colorectal cancer: validation and application. Cancer Epidemiol Biomarkers Prev; 2010 Aug;19(8):1992-2002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: CRC-SPIN simulates individual event histories associated with colorectal cancer, based on the adenoma-carcinoma sequence: adenoma initiation and growth, development of preclinical invasive colorectal cancer, development of clinically detectable colorectal cancer, death from colorectal cancer, and death from other causes.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Eur Radiol. 2010 Jun;20(6):1404-13 [20033180.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3418-22 [11151871.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2001 Mar 9;50(9):162-6 [11393486.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):1-9, v [11916153.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):183-8 [11981343.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):481-5 [14994108.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1544-50 [15307875.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):496-500 [8470627.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1116-28 [10506694.001]
  • [Cites] Am Surg. 2005 Dec;71(12):1024-6 [16447472.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):255-62 [16454827.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):389-94 [16492934.001]
  • [Cites] Gut. 2006 Aug;55(8):1145-50 [16469791.001]
  • [Cites] Stat Med. 2007 Jan 15;26(1):98-109 [16372387.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2213-21 [17455218.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Am J Prev Med. 2008 Sep;35(3):194-202 [18619761.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1218-24 [18799558.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • (PMID = 20647403.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097427-08; United States / NCI NIH HHS / CA / U01 CA097427; United States / NCI NIH HHS / CA / U01 CA097427-08; United States / NCI NIH HHS / CA / U01 CA97427
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS208492; NLM/ PMC2919657
  •  go-up   go-down


52. Ritchie KJ, Walsh S, Sansom OJ, Henderson CJ, Wolf CR: Markedly enhanced colon tumorigenesis in Apc(Min) mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A; 2009 Dec 8;106(49):20859-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markedly enhanced colon tumorigenesis in Apc(Min) mice lacking glutathione S-transferase Pi.
  • To investigate the unique functions of this enzyme, we have crossed Gstp null mice with an initiated model of colon cancer, the Apc(Min) mouse.
  • In contrast to the Apc(Min/+) Gstp1/p2(+/+) (Gstp-wt Apc(Min)) mice, which rarely develop colonic tumours, Apc(Min/+)Gstp1/p2(-/-) (Gstp-null Apc(Min)) mice had a 6-fold increase in colon adenoma incidence, and a 50-fold increase in colorectal adenoma multiplicity, relative to Gstp-wt Apc(Min).
  • Analysis of the biochemical changes in the colon tissue of Gstp-null Apc(Min) mice demonstrated a marked induction of many inflammatory genes, including IL-6, IL-4, IFN-gamma, and inducible nitric oxide synthase.
  • Gstp therefore appears to play a role in controlling inflammatory responses in the colon, which would explain the change in tumor incidence observed.
  • These data also suggest that individual variation in GSTP levels may be a factor in colon cancer susceptibility.


53. O'Connor DJ, Feinberg E, Jang J, Vemulapalli P, Camacho D: Single-incision laparoscopic-assisted right colon resection for cancer. JSLS; 2010 Oct-Dec;14(4):558-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-incision laparoscopic-assisted right colon resection for cancer.
  • INTRODUCTION: We present an approach to laparoscopic right colon resection utilizing a single port placed through the umbilicus.
  • METHODS: A 77-year-old woman with a tubulovillous adenoma in her cecum underwent a laparoscopic right colectomy using a single port placed through the umbilicus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2000 Jul-Aug;4(4):392-7 [11058851.001]
  • [Cites] Surg Endosc. 2002 May;16(5):833-5 [11997832.001]
  • [Cites] Arch Surg. 2003 Nov;138(11):1179-86 [14609864.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Aug;9(4):361-4 [10488834.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1549-55 [16235128.001]
  • [Cites] JSLS. 2007 Jan-Mar;11(1):76-80 [17651561.001]
  • [Cites] Colorectal Dis. 2010 Jan;12(1):61-5 [19320667.001]
  • [Cites] Arch Surg. 2007 Sep;142(9):823-6; discussion 826-7 [17875836.001]
  • [Cites] Urology. 2008 Jan;71(1):3-6 [18242353.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Colorectal Dis. 2009 Jan;11(1):101; author reply, 102 [19076838.001]
  • [Cites] J Gastrointest Surg. 2009 Aug;13(8):1520-3 [19365695.001]
  • [Cites] BMC Surg. 2007;7:16 [17683563.001]
  • (PMID = 21605522.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3083049
  •  go-up   go-down


54. Andersen V, Agerstjerne L, Jensen D, Østergaard M, Saebø M, Hamfjord J, Kure E, Vogel U: The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet; 2009 Feb 27;10:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study.
  • Hence, genetic variations that modify the function of P-glycoprotein may be associated with the risk of colorectal cancer (CRC).
  • The aim of this study was to investigate if this MDR1 polymorphism was associated with risk of colorectal adenoma (CA) and CRC in the Norwegian population.
  • METHODS: Using a case-control design, the association between the MDR1 intron 3 G-rs3789243-A polymorphism and the risk of colorectal carcinomas and adenomas in the Norwegian population was assessed in 167 carcinomas, 990 adenomas, and 400 controls.
  • RESULTS: No association was found between the MDR1 polymorphism (G-rs3789243-A) and colorectal adenomas or cancer.
  • Carriers of the variant allele of MDR1 intron 3 had odds ratios (95% CI) of 0.97 (0.72-1.29) for developing adenomas, and 0.70 (0.41-1.21) for colorectal cancer, respectively, compared to homozygous wild type carriers.
  • CONCLUSION: The MDR1 intron 3 (G-rs3789243-A) polymorphism was not associated with a risk of colorectal adenomas or carcinomas in the present Norwegian study group.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Genetic Predisposition to Disease. P-Glycoprotein / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 May 15;67(10):4915-23 [17510421.001]
  • [Cites] Scand J Clin Lab Invest. 2007;67(2):123-34 [17365992.001]
  • [Cites] Arch Med Res. 2007 Jul;38(5):539-44 [17560460.001]
  • [Cites] Drug Metab Dispos. 2007 Aug;35(8):1333-40 [17496207.001]
  • [Cites] BMC Cancer. 2007;7:228 [18093316.001]
  • [Cites] Curr Drug Metab. 2008 Feb;9(2):167-74 [18288958.001]
  • [Cites] Genes Immun. 2008 Sep;9(6):556-60 [18563169.001]
  • [Cites] BMC Cancer. 2008;8:326 [18992148.001]
  • [Cites] BMC Cancer. 2008;8:54 [18289367.001]
  • [Cites] Scand J Gastroenterol. 2007 Dec;42(12):1445-51 [17852840.001]
  • [Cites] Eur J Epidemiol. 2008;23(6):395-401 [18409007.001]
  • [Cites] Scand J Gastroenterol. 2009;44(1):65-73 [18819034.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1184-91 [18499698.001]
  • [Cites] Trends Biochem Sci. 2000 Jan;25(1):1-6 [10637601.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 [10716719.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):763-7 [11253971.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):725-31 [11440957.001]
  • [Cites] Genet Med. 2002 Mar-Apr;4(2):45-61 [11882781.001]
  • [Cites] Biol Pharm Bull. 2002 Oct;25(10):1356-9 [12392094.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):925-43 [12489270.001]
  • [Cites] J Womens Health (Larchmt). 2003 Mar;12(2):173-82 [12737716.001]
  • [Cites] Biochem Pharmacol. 2003 Jun 1;65(11):1843-52 [12781336.001]
  • [Cites] Pharmacogenetics. 2003 Aug;13(8):481-94 [12893986.001]
  • [Cites] Genome Res. 2004 Jul;14(7):1333-44 [15197162.001]
  • [Cites] Genome Res. 2004 Sep;14(9):1679-85 [15342553.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Semin Cancer Biol. 1997 Jun;8(3):161-70 [9441946.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Dec;311(3):1179-87 [15280437.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1243-4 [15565101.001]
  • [Cites] Eur J Cancer Prev. 2005 Aug;14(4):373-9 [16030428.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Jul;61(5-6):389-94 [15912392.001]
  • [Cites] Biochem Pharmacol. 2005 Sep 15;70(6):949-58 [16054595.001]
  • [Cites] Pharmacogenet Genomics. 2005 Oct;15(10):693-704 [16141795.001]
  • [Cites] Lancet Oncol. 2006 Feb;7(2):149-56 [16455479.001]
  • [Cites] Hum Mol Genet. 2006 Mar 1;15(5):797-805 [16434479.001]
  • [Cites] Environ Toxicol Chem. 2006 Feb;25(2):572-80 [16519321.001]
  • [Cites] Eur J Hum Genet. 2006 Apr;14(4):459-68 [16493449.001]
  • [Cites] BMC Cancer. 2006;6:67 [16542436.001]
  • [Cites] World J Gastroenterol. 2006 Jun 21;12(23):3636-44 [16773678.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):774-9 [16800822.001]
  • [Cites] Physiol Rev. 2006 Oct;86(4):1179-236 [17015488.001]
  • [Cites] Ann Intern Med. 2006 Nov 7;145(9):646-53 [17088577.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1893-6 [17096180.001]
  • [Cites] Eur J Clin Pharmacol. 2007 Jan;63(1):9-16 [17146660.001]
  • [Cites] Oncol Rep. 2007 Jul;18(1):211-7 [17549370.001]
  • (PMID = 19250544.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  • [Other-IDs] NLM/ PMC2662819
  •  go-up   go-down


55. Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, Perret C, Romagnolo B: Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res; 2006 Feb 15;66(4):1949-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the expression profiles of intestinal adenomas from a new murine familial adenomatous polyposis model (Apc(delta14/+)) using suppression subtractive hybridization to identify novel diagnostic markers of colorectal carcinogenesis.
  • We identified 18 candidate genes having increased expression levels in the adenoma.
  • Subsequent Northern blotting, real-time reverse transcription-PCR, and in situ hybridization analysis confirmed their induction in beta-catenin-activated epithelial cells of murine adenomas.
  • We showed that most of the genes also have altered expression levels in human colonic adenomas and carcinomas.
  • Using a conditional mouse model of Apc inactivation and a human colon carcinoma cell line, we showed that IFITM gene expression is rapidly induced after activation of the beta-catenin signaling.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Animals. Antigens, Differentiation. Gene Expression Regulation, Neoplastic. Humans. Intestinal Neoplasms / genetics. Intestinal Neoplasms / metabolism. Male. Mice. RNA-Binding Proteins / biosynthesis. RNA-Binding Proteins / genetics. Up-Regulation. Wnt Proteins / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488993.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers, Tumor; 0 / IFITM2 protein, human; 0 / IFITM3 protein, human; 0 / Membrane Proteins; 0 / RNA-Binding Proteins; 0 / Wnt Proteins; 0 / beta Catenin; 0 / leu-13 antigen
  •  go-up   go-down


56. Nohl H, Rohr-Udilova N, Gille L, Bieberschulte W, Jurek D, Marian B, Schulte-Herman R: Suppression of tumour-promoting factors in fat-induced colon carcinogenesis by the antioxidants caroverine and ubiquinone. Anticancer Res; 2005 Jul-Aug;25(4):2793-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of tumour-promoting factors in fat-induced colon carcinogenesis by the antioxidants caroverine and ubiquinone.
  • Addition of LOOH to the medium of LT97 adenoma and SW480 carcinoma cells enhanced the production of hydrogen peroxide.
  • High consumption of dietary fat promotes colon carcinogenesis in the long-term.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Colonic Neoplasms / prevention & control. Linoleic Acids / antagonists & inhibitors. Lipid Peroxides / antagonists & inhibitors. Quinoxalines / pharmacology. Ubiquinone / pharmacology
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Antioxidants / pharmacology. Carcinoma / genetics. Carcinoma / metabolism. Cell Line, Tumor. Dietary Fats / adverse effects. Dietary Fats / metabolism. Gene Expression / drug effects. Humans. Hydrogen Peroxide / metabolism. Hydroxyl Radical / metabolism. Linoleic Acid / administration & dosage. Linoleic Acid / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080529.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Dietary Fats; 0 / Linoleic Acids; 0 / Lipid Peroxides; 0 / Quinoxalines; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 1339-63-5 / Ubiquinone; 25657-09-4 / linoleic acid hydroperoxide; 3352-57-6 / Hydroxyl Radical; 9KJL21T0QJ / Linoleic Acid; BBX060AN9V / Hydrogen Peroxide; XJ73B0K6KB / caroverine
  •  go-up   go-down


57. Lang F, Perrotti N, Stournaras C: Colorectal carcinoma cells--regulation of survival and growth by SGK1. Int J Biochem Cell Biol; 2010 Oct;42(10):1571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent evidence disclosed the sensitivity of colon carcinoma to the expression of ubiquitous serum and glucocorticoid inducible kinase-1 (SGK1).
  • Following deficiency of APC (adenoma polyposis coli) or chemical cancerogenesis, SGK1 knockout mice develop less intestinal tumours than their wild-type littermates and pharmacological SGK1 inhibition counteracts growth of prostate cancer cells.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20541034.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Immediate-Early Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / serum-glucocorticoid regulated kinase
  •  go-up   go-down


58. Ishiguro K, Yoshida T, Yagishita H, Numata Y, Okayasu T: Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut; 2006 May;55(5):695-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas.
  • Considering the established adenoma-adenocarcinoma sequence, in this study we analysed genetic instability in colorectal adenoma cells and surrounding stroma.
  • METHODS: In 164 colorectal tumours (34 hyperplastic polyps, 38 tubular adenomas with low grade dysplasia (TA-L), 51 tubular adenomas with high grade dysplasia (TA-H), and 41 invasive carcinomas), epithelial and stromal genetic instability with National Cancer Institute standard microsatellite markers and chromosome 17 (Chr17) markers, were analysed by a combination of laser capture microdissection and GeneScan approaches.
  • RESULTS: While frequencies of both loss of heterozygosity (LOH) and microsatellite instability (MSI) were extremely low in hyperplastic polyps, LOH in tubular adenomas was detected in both epithelial (TA-L 13.2%, TA-H 27.5%) and stromal (5.3% and 5.9%, respectively) elements, along with MSI (5.3% and 13.7%, and 5.3 and 5.9%, respectively).
  • On the other hand, frequencies of stromal LOH or MSI were almost constant (5.3% approximately 17.1%, 5.3% approximately 17.1%, respectively) in adenomas and invasive carcinomas.
  • Thus microenvironmental changes due to genetic alteration in Chr17 markers in stromal cells may play an important role in colon adenoma and adenocarcinoma development.
  • [MeSH-major] Adenoma / genetics. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 17. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Genomic Instability

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1994 Jun;7(2 Spec No):246-339 [7545953.001]
  • [Cites] Genomics. 1993 Sep;17(3):618-23 [8244378.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):40-5 [8978341.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):913-21 [9492020.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2562-6 [10811140.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1617-28 [11092522.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2236-8 [11956075.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2447-54 [11980631.001]
  • [Cites] J Pathol. 2003 Feb;199(2):166-75 [12533829.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):723-30 [12760292.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):707-12 [12915883.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6158-61 [14559796.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:845-9 [4851945.001]
  • [Cites] Gastroenterology. 1974 Oct;67(4):636-45 [4414719.001]
  • [Cites] N Engl J Med. 1987 Jun 25;316(26):1654-8 [3295551.001]
  • [Cites] Dig Dis Sci. 1988 Jun;33(6):673-8 [3371139.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):75-9 [2296606.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • (PMID = 16354798.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1856111
  •  go-up   go-down


59. Pallante P, Terracciano L, Carafa V, Schneider S, Zlobec I, Lugli A, Bianco M, Ferraro A, Sacchetti S, Troncone G, Fusco A, Tornillo L: The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer; 2010 Aug;46(12):2304-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients.
  • CBX7 expression is reduced or absent in a significant number of CRC samples in comparison to the normal colonic mucosa and the loss of CBX7 expression correlates with a poor outcome of CRC (p<0.001).
  • The block of CBX7 expression seems to occur at a transcriptional level since quantitative RT-PCR analysis showed a reduced CBX7-specific mRNA levels in CRC samples versus normal counterpart tissue (up to more than 50-fold).
  • Finally, the restoration of CBX7 expression in two CRC cell lines reduces their proliferation rate suggesting a role of the loss of CBX7 expression in the progression step of colon carcinogenesis.
  • Therefore, the data reported here indicate that the evaluation of CBX7 expression may represent a valid tool in the prognosis of colon cancer since a reduced survival of CRC patients is associated with the loss of CBX7 expression.
  • [MeSH-major] Adenoma / mortality. Biomarkers, Tumor / genetics. Colonic Neoplasms / mortality. Repressor Proteins / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542683.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CBX7 protein, human; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


60. Neklason DW, Stevens J, Boucher KM, Kerber RA, Matsunami N, Barlow J, Mineau G, Leppert MF, Burt RW: American founder mutation for attenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol; 2008 Jan;6(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American founder mutation for attenuated familial adenomatous polyposis.
  • BACKGROUND & AIMS: Specific mutations in the adenomatous polyposis coli (APC) gene can lead to an attenuated form of familial adenomatous polyposis (AFAP).
  • Although AFAP mutation carriers have a 69% risk of colorectal cancer by age 80, clinical recognition remains a challenge in some cases because they present with few colonic adenomas and are difficult to distinguish clinically from patients with sporadic polyps.
  • The data show that 36.6% of the mutation-positive family members have fewer than 10 colonic adenomatous polyps, and 3 (6.8%) of these individuals were diagnosed with colorectal cancer.
  • CONCLUSIONS: In view of the apparent age of this mutation, a notable fraction of both multiple-adenoma patients and perhaps even colon cancer cases in the United States could be related to this founder mutation.
  • The colon cancer risk associated with the mutation makes genetic testing of considerable importance in patients with a personal or family history of either colonic polyps or cancer at a young age.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Sep 22;9(15):2215-21 [11001924.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):198-213 [11438509.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2954-8 [11867715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8161-6 [12034871.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2961-7 [12393807.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Trends Biotechnol. 2003 Mar;21(3):113-6 [12628367.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1250-60 [14624392.001]
  • [Cites] JAMA. 2004 Feb 11;291(6):718-24 [14871915.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):444-51 [15300576.001]
  • [Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):904-8 [2156161.001]
  • [Cites] J Med Genet. 1991 May;28(5):289-96 [1650842.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Cell. 1993 Dec 3;75(5):951-7 [8252630.001]
  • [Cites] Hum Genet. 1994 Mar;93(3):281-6 [8125478.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):705-10 [8522331.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2427-33 [8625067.001]
  • [Cites] Ann Intern Med. 1997 Apr 1;126(7):514-9 [9092316.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):385-8 [9843214.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1857-60 [10213492.001]
  • [Cites] Am J Med Genet. 1999 Oct 8;86(4):321-4 [10494086.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):388-98 [10598803.001]
  • [Cites] Am J Hum Genet. 2000 Sep;67(3):582-90 [10924409.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 1;158(1):70-4 [15771908.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1696-716 [15887160.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • (PMID = 18063416.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / NCI-CN-67000; United States / NCI NIH HHS / CA / P01-CA073992; United States / NCI NIH HHS / CA / R01 CA040641-21; United States / NCI NIH HHS / CA / R01 CA040641; United States / NCI NIH HHS / CA / P01 CA073992-10; United States / NCI NIH HHS / CA / CA040641-21; United States / NCI NIH HHS / CN / N01 CN067000; United States / NCI NIH HHS / CA / R01-CA040641; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / CA / CA073992-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS37623; NLM/ PMC2245898
  •  go-up   go-down


61. Morita M, Tabata S, Tajima O, Yin G, Abe H, Kono S: Genetic polymorphisms of CYP2E1 and risk of colorectal adenomas in the Self Defense Forces Health Study. Cancer Epidemiol Biomarkers Prev; 2008 Jul;17(7):1800-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of CYP2E1 and risk of colorectal adenomas in the Self Defense Forces Health Study.
  • We investigated the relation of these genetic polymorphisms and colorectal adenoma, a well-established precursor lesion of colorectal cancer.
  • Subjects were 455 cases of colorectal adenomas and 1,052 controls of normal colonoscopy among men receiving a preretirement health examination in the Self Defense Forces.
  • Individuals with RsaI c2 allele showed a decreased risk of proximal colon adenomas; adjusted odds ratios (95% confidence interval) of proximal and distal adenomas for the c1/c2 or c2/c2 genotype versus c1/c1 was 0.61 (0.41-0.88) and 0.95 (0.71-1.27), respectively.
  • CYP2E1 96-bp insertion allele was associated with an increased risk of large (> or = 5 mm) adenomas; adjusted odds ratios (95% confidence interval) of large and small adenomas for having at least one insertion allele were 1.41 (1.03-1.94) and 0.94 (0.71-1.25), respectively.
  • A suggestive effect modification was noted for alcohol consumption on the association between RsaI polymorphism and proximal adenomas (P(interaction) = 0.09) as well as on the association between 96-bp insertion and large adenomas (P(interaction) = 0.05).
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Cytochrome P-450 CYP2E1 / genetics. DNA, Neoplasm / genetics. Health Surveys. Military Personnel / statistics & numerical data. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628434.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.14.13.- / Cytochrome P-450 CYP2E1
  •  go-up   go-down


62. Benson ME, Reichelderfer M, Said A, Gaumnitz EA, Pfau PR: Variation in colonoscopic technique and adenoma detection rates at an academic gastroenterology unit. Dig Dis Sci; 2010 Jan;55(1):166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in colonoscopic technique and adenoma detection rates at an academic gastroenterology unit.
  • The purpose of this research is to evaluate the quality of colonoscopy at an academic institution with a focus on factors influencing withdrawal times and adenoma detection rates.
  • Per individual gastroenterologist, the adenoma detection rates ranged widely from 0.09 to 0.82 adenomas per patient with a mean of 0.46 for the group.
  • There was a significant positive relationship between the number of adenomas detected and the withdrawal time (P = 0.006).
  • Endoscopists with cecal intubation time to withdrawal time ratios of less than 1 detected significantly more adenomas compared to endoscopists with ratios greater than 1 (P = 0.001). (1) Significant variation in academic gastroenterologists' abilities to detect adenomas during screening colonoscopies exists. (2) Colonoscopic withdrawal time and the cecal intubation to withdrawal time ratio are important factors associated with increased adenoma detection rates.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy / methods
  • [MeSH-minor] Academic Medical Centers. Clinical Competence. Colonic Polyps / diagnosis. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2726-30 [17227519.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):492-6 [9434214.001]
  • [Cites] Gastrointest Endosc. 2000 Nov;52(5):606-10 [11060183.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):3182-5 [12492208.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):497-502 [9434215.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):72-7 [15017635.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 15;24(6):965-71 [16948808.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1247-56 [15131784.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1941-5 [15447753.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):481-5 [14994108.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1296-308 [12094842.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):125-7 [2032595.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • (PMID = 19156519.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kawano A, Ishikawa H, Akedo I, Nakamura T, Matsumoto K, Takayama H, Imaoka A, Umesaki Y, Tanaka R, Otani T, Sakai T: Effect of Lactobacillus casei on Streptococcus bovis in faecal flora. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a man with colon adenoma who had a high proportion of S bovis in his faecal flora.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22242064.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028456
  •  go-up   go-down


64. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.
  • However, we show here that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 09-0791; United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


65. Tamiolakis D, Venizelos I: Inverse correlation between HLA-DR antigen expression and CD4 positive lymphocytic populations in normal mucosa, tubulovillous adenoma, and invasive carcinoma of the colon. Cesk Patol; 2006 Apr;42(2):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse correlation between HLA-DR antigen expression and CD4 positive lymphocytic populations in normal mucosa, tubulovillous adenoma, and invasive carcinoma of the colon.
  • BACKGROUND: HLA-A,B,C and HLA-D molecules present antigenic peptides to the antigen-specific receptor of autologous T lymphocytes.
  • In this study we used immunohistochemistry to analyse the expression of HLA-DR on epithelial cells of normal colonic mucosa, tubulovillous adenoma, and invasive carcinoma, as well as the magnitude of the stromal T lymphocytes at the relevant sites.
  • Yet, we investigated the association of HLA-DR plus DQ genes and adenoma or carcinoma by PCR.
  • MATERIALS AND METHODS: 31 cases of normal colonic mucosa, 12 cases of tubulovillous adenoma, and 39 cases of invasive carcinoma were surveyed for the detection of HLA-DR monoclonal antigen, and the T helper (TH) marker (CD4) in the stroma (lamina propria) of the relevant cases.
  • RESULTS: HLA-DR was expressed in 20 of 31 normal colonic mucosas (64.5%), 4 of 12 adenomas (33.3%), and in 10 of 39 invasive carcinomas (25.6%).
  • No significant correlation between HLA-DR plus DQ genes and adenoma or cancer of the colon was found.
  • CD4 positive cells were found in 9 of 31 normal colonic mucosas (29%), 5 of 12 adenomas (42%), and in 26 of 39 invasive carcinomas (67%).
  • HLA-DR was significantly associated with tumor grade but not with Dukes stage in colonic cancer hosts.
  • HLA-DR and DQ genes do not contribute to a susceptibility to adenoma or carcinoma.
  • [MeSH-major] Adenoma, Villous / immunology. CD4-Positive T-Lymphocytes / pathology. Carcinoma / immunology. Colonic Neoplasms / immunology. HLA-DR Antigens / analysis. Intestinal Mucosa / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Saudi Med. 2009 Nov-Dec;29(6):489 [20232495.001]
  • (PMID = 16715627.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Duplicate Publication; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / HLA-DR Antigens
  •  go-up   go-down


66. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW: Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res; 2008 May 1;68(9):3251-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report for the first time that genetic deletion of mPGES-1 in Apc-mutant mice results in marked and persistent suppression of intestinal cancer growth by 66%, whereas suppression of large adenomas (>3 mm) was almost 95%.
  • However, we found that mPGES-1 deficiency was associated with a disorganized vascular pattern within primary adenomas as determined by CD31 immunostaining.
  • We also examined the effect of mPGES-1 deletion on carcinogen-induced colon cancer.
  • Importantly, mPGES-1 deletion also blocked the nuclear accumulation of beta-catenin in ACF, confirming that beta-catenin is a critical target of PGE(2) procarcinogenic signaling in the colon.
  • [MeSH-major] Adenoma / genetics. Gene Deletion. Intestinal Neoplasms / genetics. Intramolecular Oxidoreductases / genetics
  • [MeSH-minor] Animals. Cell Proliferation. Dinoprostone / metabolism. Disease Progression. Female. Homozygote. Intestinal Polyps / genetics. Intestinal Polyps / metabolism. Intestinal Polyps / pathology. Intestine, Small / blood supply. Intestine, Small / metabolism. Isoenzymes / genetics. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Protein Transport. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451151.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-114635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / beta Catenin; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


67. Schindler AE: Long-term use of progestogens: colon adenoma and colon carcinoma. Gynecol Endocrinol; 2007 Oct;23 Suppl 1:42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term use of progestogens: colon adenoma and colon carcinoma.
  • Colon cancer is the second most common cancer in women in the Western world and there is a trend towards an increasing risk.
  • Colon adenoma is a potential precursor for colon cancer.
  • Adenoma and carcinoma of the colon seem to be influenced by estrogens and progesterone/progestins.
  • This is related to the presence of estrogen and progesterone receptors, with apparently higher concentrations in colon cancers than in adenomas.
  • Epidemiological data and the finding of a significant reduction in colon cancer risk related to hormone replacement therapy (HRT), and in particular the length of HRT intake, indicate that progesterone/progestins have a preventive effect.
  • Furthermore, the recurrence rate of adenoma appears to be reduced, and the survival of colon cancer patients improved, with HRT; such effects have not been documented with ERT.
  • [MeSH-major] Adenoma / prevention & control. Carcinoma / prevention & control. Colonic Neoplasms / prevention & control. Hormone Replacement Therapy. Progestins / administration & dosage

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943538.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins
  • [Number-of-references] 22
  •  go-up   go-down


68. Kim Y, Kim Y, Lee S: An association between colonic adenoma and abdominal obesity: a cross-sectional study. BMC Gastroenterol; 2009;9:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An association between colonic adenoma and abdominal obesity: a cross-sectional study.
  • BACKGROUND: Colorectal adenoma is a precursor lesion of colorectal cancer and thus, it is an important target for preventing colorectal cancer.
  • Only a few studies suggest an association between colorectal adenoma and obesity, but results show considerable heterogeneity.
  • In this study, we investigated the association between colorectal adenoma and waist circumference.
  • METHODS: 165 adenoma cases and 365 polyp-free controls with a normal colon were compared in this cross-sectional study.
  • And smokers and men were more prevalent among cases than controls.Among the abdominal obese subjects, 45.6% had 1 or more adenoma, and 9.0% of these had advanced adenoma, whereas among subjects with a normal waist circumference, only 25.7% had 1 or more adenomas.
  • The prevalence of adenoma was higher among abdominal obese group (P < 0.05).
  • Logistic regression analysis showed that abdominal obesity was associated with an increased risk of colorectal adenoma (OR, 2.74; 95% CI, 1.66~4.51 in men, OR, 2.58; 95% CI, 1.08~6.12 in women).
  • While BMI was found to be weekly associated with the risk of adenoma among men at the highest BMI levels.
  • However, BMI was not associated with the risk for adenoma after adjusting for waist circumference.
  • CONCLUSION: Our data suggest that abdominal obesity is associated with an increased risk of colorectal adenoma.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):805-11 [10543250.001]
  • [Cites] Gut. 2008 Aug;57(8):1166-76 [18628378.001]
  • [Cites] Nutr Cancer. 2000;37(1):19-26 [10965515.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1296-301 [10982546.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Am J Epidemiol. 2000 Nov 1;152(9):847-54 [11085396.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):346-9 [11487263.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] J Endocrinol Invest. 2002 Nov;25(10):876-83 [12508950.001]
  • [Cites] Am J Prev Med. 2003 Feb;24(2):170-6 [12568823.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):309-14 [12578511.001]
  • [Cites] Am J Epidemiol. 2003 Sep 1;158(5):424-31 [12936897.001]
  • [Cites] J Clin Invest. 1983 Sep;72(3):1150-62 [6350364.001]
  • [Cites] Jpn J Cancer Res. 1989 Jan;80(1):51-8 [2540132.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):372-5 [2406206.001]
  • [Cites] Cancer Causes Control. 1991 Mar;2(2):117-24 [1873436.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1101-8 [1312970.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Jpn J Cancer Res. 1994 May;85(5):479-84 [8014105.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):327-34 [7847643.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):161-5 [9754646.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] Am J Epidemiol. 1999 Oct 15;150(8):869-77 [10522658.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3642-6 [15897559.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Jan;75(1):72-80 [16735075.001]
  • [Cites] Swiss Med Wkly. 2007 Jan 27;137(3-4):50-6 [17299670.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2208-25 [17498513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2533-47 [18086756.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1160-5 [18546286.001]
  • [Cites] Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S53-60 [10772419.001]
  • (PMID = 19144203.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2635368
  •  go-up   go-down


69. Bauer VP, Papaconstantinou HT: Management of serrated adenomas and hyperplastic polyps. Clin Colon Rectal Surg; 2008 Nov;21(4):273-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of serrated adenomas and hyperplastic polyps.
  • The benign serrated architecture of the hyperplastic polyp has now been recognized in morphologically similar lesions with potential for transformation to colorectal carcinoma: the sessile serrated adenoma (SSA), traditional serrated adenoma (TSA), and mixed polyp.
  • These represent a group of serrated polyps with potential to evolve into colorectal cancer through a different molecular pathway than the traditional adenoma-carcinoma sequence, called the serrated pathway.
  • An evidence-based algorithm for the clinical management of this polyp has yet to be determined.
  • Current recommendations suggest these lesions be managed similar to conventional adenomas.
  • The histology of serrated polyps is reviewed, as well as the common characteristics, and implications for treatment and surveillance.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Am J Surg Pathol. 1980 Apr;4(2):127-33 [7377462.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1309-13 [11005503.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3053-63 [11095318.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):177-84 [11176066.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):773-5 [12817423.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):778-96 [12817424.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):237-42 [14639609.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Histopathology. 2006 Aug;49(2):121-31 [16879389.001]
  • [Cites] Semin Diagn Pathol. 2005 Nov;22(4):301-8 [16939058.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] World J Gastroenterol. 2007 Jul 28;13(28):3792-8 [17657832.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):947-68, viii [17996799.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] J Clin Pathol. 1994 Oct;47(10):880-5 [7962600.001]
  • [Cites] Am J Gastroenterol. 1994 Jan;89(1):123-5 [8273780.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] J Pathol. 1996 May;179(1):20-5 [8691339.001]
  • [Cites] Lancet. 1999 Nov 27;354(9193):1873-4 [10584726.001]
  • (PMID = 20011438.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780250
  • [Keywords] NOTNLM ; Hyperplastic polyp / management / mixed polyp / sessile serrated adenoma / traditional serrated adenoma
  •  go-up   go-down


70. Vinikoor LC, Galanko JA, Sandler RS: Cholecystectomy and the risk of colorectal adenomas. Dig Dis Sci; 2008 Mar;53(3):730-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholecystectomy and the risk of colorectal adenomas.
  • Cholecystectomy has been identified as a risk factor for colorectal cancer, yet little attention has been given to the relationship between cholecystectomy and colorectal adenomas.
  • Utilizing data collected in two large cross-sectional studies of colorectal adenoma risk factors, we examined the association between cholecystectomy and colorectal adenomas.
  • In the adjusted logistic regression model, both men and women showed no effect of cholecystectomy on risk of colorectal adenomas (men: OR 0.67 [95% CI 0.30-1.47]; women: OR 1.46 [95% CI 0.92-2.29]).
  • Thus, we conclude that, although cholecystectomy is a risk factor for colorectal cancer, cholecystectomy is not a risk factor for colorectal adenomas.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Jun;181(6):526-8 [11513778.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1813-20 [16086719.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):79-83 [12556963.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2959-67 [14665657.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):187-93 [15470530.001]
  • [Cites] Gut. 1984 Aug;25(8):863-6 [6745725.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Gut. 1986 Oct;27(10):1181-5 [3781331.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):618-21 [3338028.001]
  • [Cites] Dig Dis Sci. 1988 Sep;33(9):1178-84 [3409804.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Jan;71(1):37-9 [2923417.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):58-64 [2081241.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1644-7 [1893365.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):130-41 [8514030.001]
  • [Cites] Scand J Gastroenterol. 1996 Feb;31(2):160-9 [8658039.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):41-6 [9934729.001]
  • [Cites] Am J Epidemiol. 1999 Sep 15;150(6):547-51 [10489992.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):542-7 [11522737.001]
  • (PMID = 17710546.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA044684; United States / NCI NIH HHS / CA / R01 CA044684-17; United States / NIDDK NIH HHS / DK / P30 DK034987-24; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NIDDK NIH HHS / DK / T32 DK07634; United States / NCI NIH HHS / CA / CA044684-17; United States / NIDDK NIH HHS / DK / DK034987-24; United States / NIDDK NIH HHS / DK / T32 DK007634-19; United States / NIDDK NIH HHS / DK / T32 DK007634; United States / NIDDK NIH HHS / DK / R01 DK 44684; United States / NIDDK NIH HHS / DK / P30 DK34987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS92903; NLM/ PMC2647516
  •  go-up   go-down


71. Foltyn W, Kos-Kudla B, Strzelczyk J, Matyja V, Karpe J, Rudnik A, Marek B, Kajdaniuk D, Sieron A, Latos W: Is there any relation between hyperinsulinemia, insulin resistance and colorectal lesions in patients with acromegaly? Neuro Endocrinol Lett; 2008 Feb;29(1):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Pathogenesis of colonic lesions in patients with acromegaly remains still unclear.
  • RESULTS: Colon pathologies (60 polyps and 2 flat lesions) were discovered in 19 (47.5%) patients with acromegaly, 8 of them had multiple polyps.
  • Hyperplastic polyps were revealed in 11 (27.5%), while adenomas in 8 (20%) acromegalics.
  • Patients with colorectal lesions were found to have higher WHR then subjects with normal colon (p=0.033).
  • Positive correlation between the number of hyperplastic polyps in the patients with multiple changes in the colon and IGF-1 (p=0.025), insulin level (p=0.005) and HOMA-IR (p=0.001) was found.
  • Multiple adenomas correlated positively with insulin level (p=0.007), HOMA-IR (p=0.006) and BMI (p=0.015).
  • CONCLUSIONS: The study results show a relation between hyperinsulinemia, insulin resistance and colon pathologies in acromegaly.
  • Fasting insulin level and HOMA-IR correlate positively with the number of hyperplastic polyps and adenomas in acromegalic patients with multiply colorectal lesions.
  • [MeSH-major] Acromegaly / complications. Adenoma / etiology. Colonic Polyps / etiology. Colorectal Neoplasms / etiology. Hyperinsulinism / complications. Insulin Resistance / physiology

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283256.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


72. Siddiqui AA, Maddur H, Naik S, Cryer B: The association of elevated HbA1c on the behavior of adenomatous polyps in patients with type-II diabetes mellitus. Dig Dis Sci; 2008 Apr;53(4):1042-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of elevated HbA1c on the behavior of adenomatous polyps in patients with type-II diabetes mellitus.
  • The aim of our study was to determine whether poor control of diabetes mellitus (DM) is associated with increased prevalence of colonic adenomatous polyps (APs), especially those that are advanced .
  • Significant variables by UA were included in a stepwise logistic regression analysis to determine independent predictors of aggressive clinical behavior by the polyps.
  • Logistic regression, as measured by HbA1c, demonstrated that poorly controlled DM-2 independently predicted a greater prevalence of right-sided AP, a more advanced lesion at the time of presentation, a greater number of polyps, and greater use of exogenous insulin.
  • [MeSH-major] Adenomatous Polyps / blood. Adenomatous Polyps / pathology. Colonic Neoplasms / blood. Colonic Neoplasms / pathology. Diabetes Mellitus, Type 2 / blood. Hemoglobin A, Glycosylated / metabolism

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - A1C.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1978 Apr 7;200(4337):21-7 [635569.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):972-80 [12096082.001]
  • [Cites] Diabetes Care. 2003 Jan;26 Suppl 1:S33-50 [12502618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):412-8 [12750235.001]
  • [Cites] Jpn J Cancer Res. 1989 Jan;80(1):51-8 [2540132.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):1013-5 [8959325.001]
  • [Cites] Int J Epidemiol. 1998 Oct;27(5):794-8 [9839735.001]
  • [Cites] J Gen Intern Med. 2000 Aug;15(8):551-5 [10940146.001]
  • [Cites] Annu Rev Public Health. 2005;26:445-67 [15760297.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):417-22 [11161410.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5 [15824155.001]
  • [Cites] Clin Chem. 1986 Oct;32(10 Suppl):B64-70 [3530542.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):915-9 [15184246.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):925-43 [12489270.001]
  • [Cites] Clin Biochem. 1998 Jun;31(4):221-8 [9646944.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):837-53 [9742976.001]
  • [Cites] Semin Gastrointest Dis. 2000 Oct;11(4):194-206 [11057947.001]
  • [Cites] Gut. 1999 Jul;45(1):45-50 [10369703.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Ann Intern Med. 1993 Oct 15;119(8):836-43 [8379605.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Nutr Cancer. 1997;27(3):316-20 [9101563.001]
  • [Cites] Carcinogenesis. 1985 Jul;6(7):1063-6 [4017173.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Am J Epidemiol. 1998 May 1;147(9):816-25 [9583711.001]
  • [Cites] Cancer Causes Control. 1995 Mar;6(2):164-79 [7749056.001]
  • [Cites] Arch Intern Med. 2004 Nov 8;164(20):2235-40 [15534160.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):937-41 [11535544.001]
  • [Cites] Carcinogenesis. 1993 Apr;14(4):777-9 [8472347.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1897-905 [7706497.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):107-13 [11136321.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):542-7 [10088625.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):607-12 [8824362.001]
  • [Cites] Ann Intern Med. 2004 Jun 1;140(11):945-50 [15172919.001]
  • [Cites] Diabetes Care. 1992 Jul;15(7):815-9 [1516497.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1225-31 [16979948.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1872-9 [16790032.001]
  • (PMID = 17939046.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hemoglobin A, Glycosylated; 0 / hemoglobin A1c protein, human
  •  go-up   go-down


73. Horii J, Hiraoka S, Kato J, Saito S, Harada K, Fujita H, Kaji E, Yamamoto K: Methylation of estrogen receptor 1 in colorectal adenomas is not age-dependent, but is correlated with K-ras mutation. Cancer Sci; 2009 Jun;100(6):1005-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of estrogen receptor 1 in colorectal adenomas is not age-dependent, but is correlated with K-ras mutation.
  • The methylation status of ESR1 in 105 colorectal adenoma tissues was examined by MethyLight and presented as the percentage of methylated references (PMR).
  • Factors that affect the PMR of ESR1 in adenomas were determined using parameters including patient age, sex, past history of malignancy, family history of colorectal cancer, smoking and drinking habits, clinical characteristics of adenomas (location, size, macroscopic appearance, and histology), and K-ras mutation.
  • K-ras mutation was significantly correlated with the higher methylation status of ESR1 in adenoma (t-value = 3.21, P = 0.0018), whereas alcohol exposure was significantly correlated with lower methylation status (t-value = -2.37, P = 0.02).
  • Thus, the methylation status of ESR1 in adenomas was not correlated with patient age, but was associated with K-ras mutation, suggesting that methylation of ESR1 in tumors functions differently from that in normal colon mucosa.
  • [MeSH-major] Adenoma / genetics. Adenoma / metabolism. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Estrogen Receptor alpha / genetics. Estrogen Receptor alpha / metabolism. Genes, ras. Mutation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302287.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / DNA Primers; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
  •  go-up   go-down


74. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • The methylation status of eleven genes (ADAMTS1, CDKN2A, CRABP1, HOXA9, MAL, MGMT, MLH1, NR3C1, PTEN, RUNX3, and SCGB3A1) was determined in 154 tissue samples including normal mucosa, adenomas, and carcinomas of the colorectum.
  • The gene-specific and widespread methylation status among the carcinomas was related to patient gender and age, and microsatellite instability status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • Widespread methylation was found in both adenomas and carcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


75. Levine JS, Ahnen DJ: Clinical practice. Adenomatous polyps of the colon. N Engl J Med; 2006 Dec 14;355(24):2551-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical practice. Adenomatous polyps of the colon.
  • [MeSH-major] Adenoma / diagnosis. Adenomatous Polyps / diagnosis. Colonic Neoplasms / diagnosis. Colonic Polyps / diagnosis
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colonoscopy. Humans. Male. Middle Aged. Neoplasms, Second Primary / prevention & control. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2006 Dec 14;355(24):2588-9 [17167143.001]
  • (PMID = 17167138.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 48
  •  go-up   go-down


76. Hariri LP, Tumlinson AR, Besselsen DG, Utzinger U, Gerner EW, Barton JK: Endoscopic optical coherence tomography and laser-induced fluorescence spectroscopy in a murine colon cancer model. Lasers Surg Med; 2006 Apr;38(4):305-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic optical coherence tomography and laser-induced fluorescence spectroscopy in a murine colon cancer model.
  • This study applies these technologies to a murine model of colorectal adenoma.
  • STUDY DESIGN/MATERIALS AND METHODS: The lower colon of 10 Apc(Min) and two C57BL/6J mice was surveyed over five 4-week intervals using a prototype 2.0 mm diameter OCT-LIF endoscope-based system.
  • Four categories were histologically classified: control C57BL/6J, adenomatous, non-diseased regions of adenomatous, and non-diseased Apc(Min).
  • One adenoma was histologically identified; OCT visualized mucosal thickening/abnormal mass development over the imaging timepoints.
  • LIF spectral comparisons revealed decreased 405 nm intensity and the presence of a peak at 680 nm in the adenomatous Apc(Min).
  • CONCLUSIONS: These preliminary data indicate endoscopic OCT-LIF has the potential to identify colorectal adenomas in murine models.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16596657.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109385; United States / NCI NIH HHS / CA / CA083148; United States / NCI NIH HHS / CA / CA095060; United States / NCI NIH HHS / CA / CA109385
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


77. Saar B, Meining A, Beer A, Settles M, Helmberger H, Frimberger E, Rummeny EJ, Rösch T: Prospective study on bright lumen magnetic resonance colonography in comparison with conventional colonoscopy. Br J Radiol; 2007 Apr;80(952):235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prior to MRC, the cleansed colon was filled with a gadolinium-water solution.
  • After division of the colon into five segments, interactive data analysis was carried out using three-dimensional post-processing, including a virtual intraluminal view.
  • Image quality was diagnostic in 92% (574/620 colonic segments).
  • Five flat adenomas and 6/16 small polyps (< or =5 mm) were not identified by MRC.
  • Improved MRC techniques are needed to detect small polyps and flat adenomas.
  • [MeSH-minor] Adenoma / diagnosis. Adult. Aged. Aged, 80 and over. Colonic Polyps / diagnosis. Colonoscopy / methods. Feasibility Studies. Female. Humans. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329681.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS, Lee JS: Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis; 2009 Feb;24(2):209-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced T- and N-category tumors and patients with synchronous adenoma displayed higher chemosensitivity to CG-3, CG-2, and CG-1, respectively, on a multivariate analysis (P = 0.023, 0.044, and 0.045, respectively).
  • Additionally, tumor growth and heredity were significantly associated with specific regimens, supporting their possible role as chemosensitive predictors.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2004 May;5(5):455-63 [15144953.001]
  • [Cites] Anticancer Drugs. 2003 Jun;14(5):369-75 [12782944.001]
  • [Cites] Proc Nutr Soc. 2003 Feb;62(1):107-15 [12740065.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6693-701 [15235588.001]
  • [Cites] Nat Biotechnol. 2007 Jan;25(1):84-90 [17211407.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2185-91 [10473104.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jun;131(6):385-94 [15754201.001]
  • [Cites] Int J Clin Oncol. 2005 Oct;10 (5):328-32 [16247659.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):305-11 [9815986.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jul;60(2):275-83 [17124594.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5276-82 [7585588.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):489-501 [17428170.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98 [17428177.001]
  • [Cites] Head Neck. 2002 May;24(5):437-42 [12001073.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1537-43 [9815954.001]
  • [Cites] Dis Colon Rectum. 1999 May;42(5):640-8 [10344687.001]
  • [Cites] Biochem Soc Trans. 2004 Dec;32(Pt 6):1095-7 [15506976.001]
  • [Cites] Surg Oncol. 2007 Jul;16(1):65-70 [17521906.001]
  • [Cites] Methods Mol Med. 2005;110:79-86 [15901929.001]
  • [Cites] J Biolumin Chemilumin. 1994 Nov-Dec;9(6):373-8 [7879653.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Aug;60(3):437-46 [17377791.001]
  • [Cites] Oncology. 2004;66(1):46-52 [15031598.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Nov 1;192(3):237-45 [14575641.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):225-7 [15655355.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):477-87 [17428169.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G696-703 [16160080.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1957-62 [14738150.001]
  • [Cites] Biochem Pharmacol. 2007 Sep 1;74(5):659-71 [17498667.001]
  • [Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3224-9 [17664470.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):445-52 [15882168.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8778-81 [15574791.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33 [3474637.001]
  • (PMID = 18830613.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors
  •  go-up   go-down


79. Zhou JN, Chen SQ, Zhang XM, Zhou X, Zhu M, Feng B, Li JT, Ma GJ, Zhang YY: [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug;23(4):388-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree].
  • OBJECTIVE: To detect the adenomatous polyposis coli (APC) gene germline mutation in the proband and her family members with familial adenomatous polyposis (FAP).
  • This mutation manifested an aggressive form of FAP with early onset of colorectal adenocarcinoma and colonic adenoma.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli Protein / genetics. Germ-Line Mutation

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883523.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  •  go-up   go-down


80. Ichihara T, Yoshino H, Doi Y, Nabae K, Imai N, Hagiwara A, Tamano S, Morita O, Tamaki Y, Suzuki H: No enhancing effects of diacylglycerol oil on tumor development in a medium-term multi-organ carcinogenesis bioassay using male F344 rats. Food Chem Toxicol; 2008 Jan;46(1):157-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Controls received standard diet without any supplementation as non-treated control.
  • The incidence of colon adenomas was significantly increased in rats given 1.375% DAG oil, but not 2.75% and 5.5% DAG oil, when compared to the control (5.5% TG group) value.
  • Furthermore, incidences and multiplicity of hyperplasias and adenomas and/or adenocarcinomas were comparable across all DAG oil-treated groups.
  • In contrast, incidences of colon adenomas and/or adenocarcinomas were significantly increased in rats given 5.5% HOTG, and adenomas with MCTG, but not 5.5% HLTG, as compared to the 5.5% TG value.
  • Thus, the current results indicate that DAG oil may not exert modifying potential on tumor development, even in the colon because of the lack of dose-dependence.
  • DAG oil was equivalent to HOTG (standard cocking oil composed of naturally occurring fatty acids), with regard to colon tumor development.
  • [MeSH-minor] Animals. Body Weight / drug effects. Colonic Neoplasms / chemically induced. Colonic Neoplasms / pathology. Diet. Drinking / drug effects. Drug Interactions. Eating / drug effects. Glutathione Transferase / metabolism. Male. Organ Size / drug effects. Rats. Rats, Inbred F344. Survival Analysis. Triglycerides / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728035.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Diglycerides; 0 / Triglycerides; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


81. Jung B, Lannerstad O, Påhlman L, Arodell M, Unosson M, Nilsson E: Preoperative mechanical preparation of the colon: the patient's experience. BMC Surg; 2007;7:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative mechanical preparation of the colon: the patient's experience.
  • BACKGROUND: Preoperative mechanical bowel preparation can be questioned as standard procedure in colon surgery, based on the result from several randomised trials.
  • METHODS: As part of a large multicenter trial, 105 patients planned for elective colon surgery for cancer, adenoma, or diverticulitis in three hospitals were asked to complete a questionnaire regarding perceived health including experience with bowel preparation.
  • [MeSH-major] Adenoma / surgery. Colonic Neoplasms / surgery. Diverticulitis, Colonic / diagnosis. Diverticulitis, Colonic / surgery. Enema. Patient Satisfaction. Preoperative Care. Therapeutic Irrigation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Pract. 1999 Sep-Oct;7(5):240-7 [10687593.001]
  • [Cites] Br J Surg. 2007 Jun;94(6):689-95 [17514668.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):363-7 [12616120.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD001544 [12804412.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] Br J Surg. 1978 Aug;65(8):555-8 [354736.001]
  • [Cites] Oncol Nurs Forum. 1984 May-Jun;11(3):92-4 [6562647.001]
  • [Cites] Pain. 1986 Oct;27(1):117-26 [3785962.001]
  • [Cites] Br J Surg. 1987 Jul;74(7):580-1 [3620862.001]
  • [Cites] World J Surg. 1993 Mar-Apr;17(2):220-5 [8511917.001]
  • [Cites] Pain. 1994 Feb;56(2):217-26 [8008411.001]
  • [Cites] Br J Surg. 1994 Jun;81(6):907-10 [8044619.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1673-6 [7827905.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):585-91 [9152189.001]
  • [Cites] Dis Colon Rectum. 1998 Jul;41(7):875-82; discussion 882-3 [9678373.001]
  • [Cites] Arch Surg. 2004 Dec;139(12):1359-64; discussion 1365 [15611462.001]
  • [Cites] Arch Surg. 2005 Mar;140(3):285-8 [15781794.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):409-14 [15786427.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1509-16 [15981065.001]
  • [Cites] Dis Colon Rectum. 2000 May;43(5):669-75; discussion 675-7 [10826429.001]
  • (PMID = 17480223.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1884131
  •  go-up   go-down


82. Park KJ, Choi HJ, Kim SH, Han SY, Hong SH, Cho JH, Kim HH: Sigmoidorectal intussusception of adenoma of sigmoid colon treated by laparoscopic anterior resection after sponge-on-the-stick-assisted manual reduction. World J Gastroenterol; 2006 Jan 7;12(1):146-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sigmoidorectal intussusception of adenoma of sigmoid colon treated by laparoscopic anterior resection after sponge-on-the-stick-assisted manual reduction.
  • We present herein a case report of sigmoidorectal intussusception as an unusual case of sigmoid adenomatous polyp.
  • An emergency colonoscopy revealed that the invaginated colon with polypoid mass was protruded to the lower rectum.
  • The permanent pathologic finding showed villotubular adenoma of the sigmoid colon.
  • [MeSH-major] Adenoma / complications. Intussusception / surgery. Laparoscopy / methods. Rectal Diseases / surgery. Sigmoid Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(2):188-90 [10664347.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):390-5 [10195723.001]
  • [Cites] J Clin Gastroenterol. 2003 Jan;36(1):18-21 [12488701.001]
  • [Cites] Surg Today. 2003;33(10):768-71 [14513327.001]
  • [Cites] Radiol Clin North Am. 2003 Nov;41(6):1137-51 [14661662.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1971 May;121(5):531-5 [5557762.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):230-6 [7469558.001]
  • [Cites] Acta Chir Scand. 1989 Mar;155(3):201-4 [2741629.001]
  • [Cites] Br J Surg. 1989 Jul;76(7):727 [2765810.001]
  • [Cites] Am Surg. 1995 Apr;61(4):320-1 [7893095.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • [Cites] Clin Radiol. 1998 Jan;53(1):53-7 [9464437.001]
  • [Cites] Aust N Z J Surg. 1998 Sep;68(9):683-5 [9737271.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4697-700 [11205203.001]
  • (PMID = 16440436.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4077479
  •  go-up   go-down


83. Ashktorab H, Brim H, Al-Riyami M, Date A, Al-Mawaly K, Kashoub M, Al-Mjeni R, Smoot DT, Al-Moundhri M, Al-Hashemi S, Ganguly SS, Raeburn S: Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects. Dig Dis Sci; 2008 Oct;53(10):2723-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects.
  • We assessed colonic cancers in an attempt to identify tumors with DNA MMR deficiency and microsatellite instability (MSI).
  • Colon cancer tissue was assayed using immunohistochemistry for expression of hMLH1 and hMSH2, and a panel of five pairs of microsatellite primers (NR21, NR22, NR24, BAT25, and BAT26) for MSI-H analysis and additional dinucleotide markers (D17S250, D5S346, and D2S123) used for MSI-L.
  • The methylation status of the p16 promoter was determined by methylation-specific polymerase chain reaction (PCR).
  • The information currently available indicates that there is an incidence of 4.7% colon cancer (49/1036) and 12.1% (126/1290) colon adenoma among the cases who underwent colonoscopy at these centers.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Colorectal Neoplasms / genetics. DNA Mismatch Repair. Microsatellite Instability

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):105-15 [8461861.001]
  • [Cites] Am J Hum Genet. 2004 Mar;74(3):532-44 [14973781.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5410-6 [16061855.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10 (1 Pt 1):191-5 [14734469.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):66-73 [12794758.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):779-85 [10091754.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5635-43 [16110022.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):123-31 [10381918.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5470-4 [8968103.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):386-95 [3422035.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Surgery. 2001 Jul;130(1):17-20 [11436007.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):952-61 [16015629.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Clin Chem Lab Med. 2001 Feb;39(2):121-8 [11341745.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):664-9 [9421366.001]
  • [Cites] Isr Med Assoc J. 2005 Aug;7(8):520-4 [16106779.001]
  • (PMID = 18299982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Mucins; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


84. East JE, Suzuki N, Stavrinidis M, Guenther T, Thomas HJ, Saunders BP: Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut; 2008 Jan;57(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer.
  • BACKGROUND: Colonoscopic surveillance for hereditary non-polyposis colorectal cancer (HNPCC) reduces death rates, but early interval cancers still occur, probably due to missed small, aggressive adenomas.
  • Narrow band imaging (NBI), a novel endoscopic technology, highlights superficial mucosal capillaries and improves contrast for adenomas.
  • This study examined whether a second pass with NBI in the proximal colon helped detect additional adenomas in patients with HNPCC.
  • All polyps detected were removed for histopathological analysis.
  • RESULTS: At least one adenoma in the proximal colon was detected during the initial white light pass in 17/62 (27%).
  • NBI detected additional adenomas in 17/62 (27%).
  • 26/62 (42%) patients had at least one adenoma detected after both white light and NBI; absolute difference 15% (95% CI 4-25%), p = 0.004 versus white light alone.
  • The total number of adenomas increased from 25 before NBI to 46 after NBI examination, p<0.001.
  • The proportion of flat adenomas detected in the NBI pass, 9/21 (45%), was higher than in the white light pass, 3/25 (12%), p = 0.03.
  • Including white light examination of the sigmoid and rectum, overall 28/62 (45%) patients had at least one adenoma detected.
  • CONCLUSIONS: Use of NBI in the proximal colon for patients undergoing HNPCC surveillance appears to improve adenoma detection, particularly those with a flat morphology.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / methods. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonic Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retreatment. Sensitivity and Specificity


85. Tuppurainen K, Mäkinen JM, Junttila O, Liakka A, Kyllönen AP, Tuominen H, Karttunen TJ, Mäkinen MJ: Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol; 2005 Nov;207(3):285-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer.
  • Colorectal serrated adenocarcinoma originates from serrated adenoma, but definite histological criteria have not yet been established.
  • To address these questions, morphological criteria for serrated cancers were established, their validity was tested, and MSI analysis was performed with NIH consensus markers and MMR enzyme immunohistochemistry for hMLH1, hMSH2, and hMSH6 in 35 serrated and 75 non-serrated colorectal carcinomas.
  • With these features, it was possible to distinguish them from non-serrated cancers, with the mean kappa score for five observers being 0.509.
  • MSI analysis was successful in 31 serrated and 73 non-serrated carcinomas.
  • 54.8% of serrated carcinomas were microsatellite-stable (MSS), 29.0% presented with MSI-L, and 16.1% presented with MSI-H, whereas 78.1% of non-serrated carcinomas were MSS, 13.7% were MSI-L, and 8.2% were MSI-H.
  • MSI-H did not differ between serrated and non-serrated cancers (p=0.14).
  • These results suggest that the biological background of serrated carcinomas differs from sporadic non-serrated colorectal cancer, but is not directly related to MSI.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Base Pair Mismatch / genetics. Biomarkers, Tumor / genetics. Carrier Proteins / genetics. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Colon / pathology. DNA, Neoplasm / genetics. Eosinophils / pathology. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Observer Variation. Rectum / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16177963.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


86. Hyman N, Moore J, Cataldo P, Osler T: The high yield of 1-year colonoscopy after resection: is it the handoff? Surg Endosc; 2010 Mar;24(3):648-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients undergoing surgery for colorectal cancer by two colon and rectal surgeons at a university hospital from 1991 to 2005 were identified from the tumor registry.
  • Fisher's exact test was used to compare the probability of finding any adenoma, advanced adenoma, or invasive cancer based on the index endoscopist.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Registries. Retrospective Studies


87. Kahi CJ, Anderson JC, Waxman I, Kessler WR, Imperiale TF, Li X, Rex DK: High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. Am J Gastroenterol; 2010 Jun;105(6):1301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Flat and depressed colon neoplasms are an increasingly recognized precursor for colorectal cancer (CRC) in Western populations.
  • The primary outcomes, patients with at least one adenoma and the number of adenomas per patient, were compared between the two groups.
  • Overall, the mean number of adenomas per patient was 1.2+/-2.1, the mean number of flat polyps per patient was 1.4+/-1.9, and the mean number of flat adenomas per patient was 0.5+/-1.0.
  • The number of patients with at least one adenoma (55.5% vs. 48.4%, absolute difference 7.1%, 95% confidence interval (-0.5% to 14.7%), P=0.07), and the number of adenomas per patient (1.3+/-2.4 vs. 1.1+/-1.8, P=0.07) were marginally higher in the chromocolonoscopy group.
  • There were no significant differences in the number of advanced adenomas per patient (0.06+/-0.37 vs. 0.04+/-0.25, P=0.3) and the number of advanced adenomas<10 mm per patient (0.02+/-0.26 vs. 0.01+/-0.14, P=0.4).
  • Chromocolonoscopy detected significantly more flat adenomas per patient (0.6+/-1.2 vs. 0.4+/-0.9, P=0.01), adenomas<5 mm in diameter per patient (0.8+/-1.3 vs. 0.7+/-1.1, P=0.03), and non-neoplastic lesions per patient (1.8+/-2.3 vs. 1.0+/-1.3, P<0.0001).
  • CONCLUSIONS: High-definition chromocolonoscopy marginally increased overall adenoma detection, and yielded a modest increase in flat adenoma and small adenoma detection, compared with high-definition white light colonoscopy.
  • The high adenoma detection rates observed in this study may be due to the high-definition technology used in both groups.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis


88. Neklason DW, Thorpe BL, Ferrandez A, Tumbapura A, Boucher K, Garibotti G, Kerber RA, Solomon CH, Samowitz WS, Fang JC, Mineau GP, Leppert MF, Burt RW, Kuwada SK: Colonic adenoma risk in familial colorectal cancer--a study of six extended kindreds. Am J Gastroenterol; 2008 Oct;103(10):2577-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenoma risk in familial colorectal cancer--a study of six extended kindreds.
  • OBJECTIVES: Most colorectal cancers (CRCs) arise from adenomatous polyps, but the effects of CRC family history on adenoma risk are not well known.
  • Known hereditary colon cancer syndromes were clinically and genetically excluded.
  • RESULTS: Thirty-seven percent of relatives were found to have adenomas on colonoscopy.
  • The average age of diagnosis for colon cancer was 63 yr and advanced adenomas 56 yr.
  • Independent predictors of adenomatous polyps in the relatives were advancing age (P < 0.0001), male gender (P < 0.001), and greater degree of relation to CRC cases (P < 0.01).
  • There was no significant predilection of colorectal tumors for the right or left colon.
  • A higher degree of relationship to CRC cases was a significant predictor of having simple and advanced adenomas, but not hyperplastic polyps after adjustment for age and gender.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Familial Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Womens Health Gend Based Med. 1999 Nov;8(9):1155-66 [10595328.001]
  • [Cites] Gut. 2005 Dec;54(12):1733-40 [15955785.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:50-9; discussion 59-61 [10911905.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):837-53 [10982778.001]
  • [Cites] Gut. 2002 Feb;50(2):228-34 [11788565.001]
  • [Cites] Am J Prev Med. 2003 Feb;24(2):190-8 [12568826.001]
  • [Cites] Gut. 2003 May;52(5):747-51 [12692063.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):9-16 [15236166.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):819-25 [7055790.001]
  • [Cites] N Engl J Med. 1985 Jun 13;312(24):1540-4 [4000184.001]
  • [Cites] Genet Epidemiol. 1986;3(1):39-52 [3957003.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):533-7 [2841598.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):252-63 [8317490.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1618-26 [7932826.001]
  • [Cites] N Engl J Med. 1994 Dec 22;331(25):1669-74 [7969357.001]
  • [Cites] Genet Epidemiol. 1995;12(3):291-301 [7557350.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):7-12 [9649451.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):385-8 [9843214.001]
  • [Cites] Am J Med. 1999 Jul;107(1):68-77 [10403355.001]
  • [Cites] Cancer. 2005 May 1;103(9):1906-15 [15779016.001]
  • [Cites] JAMA. 2005 Apr 27;293(16):1979-85 [15855431.001]
  • [Cites] Eur J Cancer Prev. 2005 Aug;14(4):373-9 [16030428.001]
  • [Cites] Fam Cancer. 2005;4(3):239-44 [16136384.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • (PMID = 18671820.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00064; United States / NCI NIH HHS / CA / P01-CA73992; United States / NCI NIH HHS / CA / P30-CA42014; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / CA / R01-CA40641; United States / NCI NIH HHS / CA / N01PC35141; United States / NCI NIH HHS / CA / R01 CA040641-21; United States / NCI NIH HHS / CA / R01 CA040641; United States / NCI NIH HHS / CA / P01 CA073992-10; United States / NCI NIH HHS / CA / CA040641-21; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / PC / N01-PC-67000; United States / NCRR NIH HHS / RR / M01 RR000064; United States / NCI NIH HHS / CA / CA073992-10; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS224182; NLM/ PMC2922112
  •  go-up   go-down


89. Martínez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, Zauber AG, Jiang R, Ahnen DJ, Bond JH, Church TR, Robertson DJ, Smith-Warner SA, Jacobs ET, Alberts DS, Greenberg ER: A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology; 2009 Mar;136(3):832-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of